WO2022181807A1 - REST mRNA前駆体のプロセシングにおけるNエキソンのスキッピングを誘導するオリゴヌクレオチド - Google Patents
REST mRNA前駆体のプロセシングにおけるNエキソンのスキッピングを誘導するオリゴヌクレオチド Download PDFInfo
- Publication number
- WO2022181807A1 WO2022181807A1 PCT/JP2022/008079 JP2022008079W WO2022181807A1 WO 2022181807 A1 WO2022181807 A1 WO 2022181807A1 JP 2022008079 W JP2022008079 W JP 2022008079W WO 2022181807 A1 WO2022181807 A1 WO 2022181807A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- oligonucleotide
- ring
- branched
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 151
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 45
- 238000012545 processing Methods 0.000 title claims abstract description 17
- 230000001939 inductive effect Effects 0.000 title claims description 16
- 239000002243 precursor Substances 0.000 title description 3
- 108010049420 RE1-silencing transcription factor Proteins 0.000 claims abstract description 100
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 167
- -1 2 -oxo-1,2-dihydropyrimidin-1-yl group Chemical group 0.000 claims description 160
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 65
- 125000003545 alkoxy group Chemical group 0.000 claims description 55
- 238000001668 nucleic acid synthesis Methods 0.000 claims description 54
- 125000006239 protecting group Chemical group 0.000 claims description 54
- 125000003277 amino group Chemical group 0.000 claims description 53
- 125000003118 aryl group Chemical group 0.000 claims description 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
- 125000003835 nucleoside group Chemical group 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 24
- 125000004414 alkyl thio group Chemical group 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 23
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 22
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 22
- 206010060862 Prostate cancer Diseases 0.000 claims description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000004434 sulfur atom Chemical group 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000005159 cyanoalkoxy group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 4
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 108020004635 Complementary DNA Proteins 0.000 abstract 1
- 102100022940 RE1-silencing transcription factor Human genes 0.000 description 89
- 210000004027 cell Anatomy 0.000 description 74
- 239000002585 base Substances 0.000 description 55
- 230000000694 effects Effects 0.000 description 53
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 47
- 239000000074 antisense oligonucleotide Substances 0.000 description 37
- 238000012230 antisense oligonucleotides Methods 0.000 description 37
- 238000000034 method Methods 0.000 description 32
- 108020004707 nucleic acids Proteins 0.000 description 30
- 102000039446 nucleic acids Human genes 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 29
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 21
- 101000829203 Homo sapiens Serine/arginine repetitive matrix protein 4 Proteins 0.000 description 19
- 102100023663 Serine/arginine repetitive matrix protein 4 Human genes 0.000 description 19
- 239000002777 nucleoside Substances 0.000 description 17
- 230000007717 exclusion Effects 0.000 description 16
- 238000003757 reverse transcription PCR Methods 0.000 description 15
- 125000002252 acyl group Chemical group 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 238000012986 modification Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
- 125000005129 aryl carbonyl group Chemical group 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001638 lipofection Methods 0.000 description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 125000004849 alkoxymethyl group Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000005103 alkyl silyl group Chemical group 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 150000004713 phosphodiesters Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 101100534274 Homo sapiens SRRM4 gene Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 101150109839 SRRM4 gene Proteins 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 150000008300 phosphoramidites Chemical group 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 108091006107 transcriptional repressors Proteins 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical class [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000756346 Homo sapiens RE1-silencing transcription factor Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 150000001484 arginines Chemical class 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001868 cobalt Chemical class 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 150000005332 diethylamines Chemical class 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 2
- 125000005921 isopentoxy group Chemical group 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical class CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 150000002780 morpholines Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002815 nickel Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000037423 splicing regulation Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003890 2-phenylbutyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101150097657 Rest gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004888 n-propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004706 n-propylthio group Chemical group C(CC)S* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Definitions
- the present invention provides an oligonucleotide that skips the N exon in pre-mRNA processing of the transcription repressor REST (RE1-silencing transcription factor), or a pharmacologically acceptable salt thereof, and a pharmaceutical comprising the same. Regarding the composition.
- SCLC small cell lung cancer
- ASO antisense nucleic acid medicine
- SRRM4 Serine/Arginine Repetitive Matrix 4
- the transcriptional repressor REST In the pathology of SCLC, the transcriptional repressor REST, a tumor suppressor, is decreased and the REST isoform (sREST) is abnormally expressed. Splicing of the transcriptional repressor REST is activated by SRRM4. It has been reported that the transcriptional repressor REST is a master molecule of nervous system genes and a tumor suppressor.
- SRRM4 antisense oligonucleotide suppresses SRRM4 and exhibits anti-tumor effects, while promoting alterations in the splicing of the tumor suppressor REST, and the resulting increase in REST expression is associated with cancer. thought to induce cell death. Furthermore, regarding sREST that is abnormally expressed in SCLC, it has been revealed that SCLC cell death can be induced by directly promoting a splicing change that causes REST to be expressed from sREST (non-patent document 1).
- the present invention is intended to solve the above problems, and its object is to provide oligonucleotides or pharmacologically acceptable salts thereof capable of appropriately inducing skipping of the N exon of REST, and pharmaceuticals containing the same.
- the object is to provide a composition.
- the present invention provides an oligo containing a nucleotide sequence complementary to a continuous sequence of at least 12 bases in the target region consisting of the nucleotide sequence of SEQ ID NO: 1, and inducing N exon skipping in processing of human REST pre-mRNA.
- a nucleotide or a pharmacologically acceptable salt thereof is provided.
- the length of the oligonucleotide is 12-35 bases.
- the oligonucleotide or a pharmacologically acceptable salt thereof has a nucleoside structure represented by the following formula (I):
- Base is a purin-9-yl group optionally having one or more arbitrary substituents selected from the ⁇ group, or optionally having one or more arbitrary substituents selected from the ⁇ group 2 -oxo-1,2-dihydropyrimidin-1-yl group, wherein the ⁇ group is a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a linear alkyl group having 1 to 6 carbon atoms, a carbon linear alkoxy group of number 1 to 6, mercapto group, mercapto group protected by protecting group for nucleic acid synthesis, linear alkylthio group of 1 to 6 carbon atoms, amino group, linear alkylamino group of 1 to 6 carbon atoms , an amino group protected by a protective group for nucleic acid synthesis, and a halogen atom, A is:
- R 1 is selected from a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, an optionally branched or ring-forming alkenyl group having 2 to 7 carbon atoms, and the ⁇ group an aryl group having 3 to 12 carbon atoms which may have one or more optional substituents and may contain a heteroatom, and one or more optional substituents selected from the ⁇ group represents an aralkyl group having an aryl moiety of 3 to 12 carbon atoms which may optionally contain a heteroatom, or an amino group-protecting group for nucleic acid synthesis;
- R 2 and R 3 are each independently a hydrogen atom; optionally substituted with an aryl group having 3 to 12 carbon atoms which may contain a heteroatom, and optionally branched or forming a ring; an alkyl group having 1 to 7 carbon atoms; or an aralkyl group having an aryl moiety having 3 to 12 carbon
- R 17 , R 18 and R 19 each independently form a hydrogen atom, a branch or a ring an alkyl group having 1 to 7 carbon atoms, an amino group-protecting group, or
- R 13 and R 14 each independently represents a hydrogen atom; a hydroxyl group; an alkyl group having 1 to 7 carbon atoms which may be branched or forming a ring; A group selected from the group consisting of an alkoxy group of 7; an amino group; and an amino group protected by a protecting group for nucleic acid synthesis; m is an integer from 0 to 2; n is an integer from 0 to 1; R 10 is a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, an amino-protecting group, or
- the linkages between nucleotides that make up the oligonucleotide contain phosphorothioate.
- the base sequence of the above oligonucleotide comprises any of the base sequences of SEQ ID NOs: 3-11 and SEQ ID NOs: 40-49.
- nucleoside structure represented by formula (I) above is
- the present invention is further a pharmaceutical composition comprising the oligonucleotide or a pharmacologically acceptable salt thereof.
- the pharmaceutical composition is a cancer therapeutic.
- the cancer therapeutic agent is used to treat at least one cancer selected from the group consisting of small cell lung cancer, prostate cancer and breast cancer.
- the pharmaceutical composition is a therapeutic agent for heart failure.
- the present invention further provides a method for treating cancer or heart failure in a mammal, which comprises administering to the mammal an effective amount of the oligonucleotide or a pharmacologically acceptable salt thereof.
- the present invention is further the above oligonucleotide or a pharmacologically acceptable salt thereof for use in treating cancer or heart failure.
- the present invention is further the oligonucleotide or a pharmacologically acceptable salt thereof for the production of a therapeutic drug for cancer or heart failure.
- N exon skipping can be induced in the processing of REST pre-mRNA.
- it can exhibit anti-tumor effects in vivo. This will be useful for the development of pharmaceutical compositions for the treatment or prevention of diseases involving REST processing (splicing) (for example, cancer such as small cell lung cancer, or heart failure).
- FIG. 2 is a graph showing the expression ratio of sREST to REST (sREST/REST) when added to SCLC cells in primary screening for various antisense oligonucleotides.
- FIG. 2 is a graph showing the expression ratio of sREST to REST (sREST/REST) for various antisense oligonucleotides when added to prostate cancer cells.
- A is a photograph of the results of RT-PCR showing altered splicing (N exon skipping) by an oligonucleotide (SSO) targeting REST
- B is a graph showing the results of evaluation of cell viability.
- FIG. 10 is a graph showing that N exon skipping of REST-targeting oligonucleotides (SSO) is concentration dependent.
- FIG. 2 shows the positional relationship of REST-targeting oligonucleotides (SSO) in REST pre-mRNA (upper panel) and the concentration dependence of N exon skipping of SSO (lower panel).
- the base sequence in the figure is shown as SEQ ID NO:50.
- REST-targeting oligonucleotides (specifically, AmNA[+23/+40] (hereinafter sometimes referred to as AmNA_2340) and AmNA[+27/+44] (hereinafter referred to as AmNA_2744) ) in REST pre-mRNA (upper diagram), and a graph (lower diagram) showing the concentration dependence of N exon skipping of SSO.
- SSO SSO
- AmNA_2340 AmNA[+27/+44]
- AmNA_2744 AmNA[+27/+44]
- the base sequence in the figure is SEQ ID NO: 51. show.
- NCs that do not change splicing are preferable, we decided to use NCs whose relative exon skipping activity is closest to 1 (NC3) as NCs in the future.
- FIG. 11 is a graph showing the results of quantifying relative exon skipping activity from the photographs of FIG. 10.
- the results of SSO analysis are summarized based on FIGS. 8, 10 and 11.
- Photographs of RT-PCR results showing the positional relationship of REST-targeting oligonucleotides (SSO) in REST pre-mRNA (upper diagram), and changes in splicing (N exon skipping) due to SSO, and relative comparisons from the photographs. It is a graph (lower figure) of the results of quantification of exon skipping activity.
- FIG. 2 shows the positional relationship of REST-targeting oligonucleotides (SSO) in REST pre-mRNA (top), and a graph of the results of quantifying relative SRRM4 expression levels by SSO (bottom).
- alkyl group having 1 to 3 carbon atoms includes any alkyl group having 1 to 3 carbon atoms. Specific examples include a methyl group, an ethyl group, an n-propyl group, and an isopropyl group.
- linear alkyl group having 1 to 6 carbon atoms includes any linear alkyl group having 1 to 6 carbon atoms. Specific examples include methyl group, ethyl group, n-propyl group, n-butyl group, n-pentyl group and n-hexyl group.
- linear alkoxy group having 1 to 6 carbon atoms includes an alkoxy group having any linear alkyl group having 1 to 6 carbon atoms. Examples include methyloxy group, ethyloxy group, n-propyloxy group and the like.
- a straight or branched chain alkoxy group having 1 to 6 carbon atoms includes an alkoxy group having any straight or branched chain alkyl group having 1 to 6 carbon atoms.
- Examples include methyloxy group, ethyloxy group, n-propyloxy group, isopropyloxy group, n-butyloxy group, isobutyloxy group, tert-butyloxy group, n-pentyloxy group and isopentyloxy group.
- linear alkylthio group having 1 to 6 carbon atoms includes an alkylthio group having any linear alkyl group having 1 to 6 carbon atoms. Examples thereof include a methylthio group, an ethylthio group and an n-propylthio group.
- a straight or branched chain alkylthio group having 1 to 6 carbon atoms includes an alkylthio group having any straight or branched chain alkyl group having 1 to 6 carbon atoms.
- Examples include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio, n-pentylthio and isopentylthio groups.
- cyanoalkoxy group having 1 to 6 carbon atoms refers to a group in which at least one hydrogen atom constituting the linear alkoxy group having 1 to 6 carbon atoms is substituted with a cyano group.
- linear alkylamino group having 1 to 6 carbon atoms refers to a group in which one or two hydrogen atoms constituting an amino group are substituted with a linear alkyl group having 1 to 6 carbon atoms. encompasses Examples thereof include methylamino group, dimethylamino group, ethylamino group, methylethylamino group and diethylamino group.
- linear or branched chain alkylamino group having 1 to 6 carbon atoms means that one or two of the hydrogen atoms constituting the amino group are any linear or branched chain having 1 to 6 carbon atoms. Includes groups substituted with chain alkyl groups.
- Examples include methylamino group, dimethylamino group, ethylamino group, methylethylamino group, diethylamino group, n-propylamino group, di-n-propylamino group, isopropylamino group and diisopropylamino group.
- any straight chain alkyl group having 1 to 7 carbon atoms includes methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and n-heptyl groups.
- Optional branched alkyl groups having 3 to 7 carbon atoms include isopropyl group, isobutyl group, tert-butyl group, isopentyl group and the like, and optional cyclic alkyl groups having 3 to 7 carbon atoms are A cyclobutyl group, a cyclopentyl group, a cyclohexyl group and the like can be mentioned.
- alkenyl group having 2 to 7 carbon atoms means any linear alkenyl group having 2 to 7 carbon atoms, any branched alkenyl group having 3 to 7 carbon atoms, Chain alkenyl groups and any cyclic alkenyl groups having 3 to 7 carbon atoms are included. It may simply be referred to as a "lower alkenyl group”.
- any linear alkenyl group having 2 to 7 carbon atoms includes ethenyl group, 1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1-hexenyl group and the like
- arbitrary branched alkenyl groups having 3 to 7 carbon atoms include isopropenyl group, 1-methyl-1-propenyl group, 1-methyl -2-propenyl group, 2-methyl-1-propenyl group, 2-methyl-2-propenyl group, 1-methyl-2-butenyl group and the like
- any cyclic alkenyl group having 3 to 7 carbon atoms includes a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, and the like.
- any linear alkoxy group having 1 to 7 carbon atoms includes methoxy, ethoxy, n-propoxy, n-butyroxy, n-pentyloxy, n-hexyloxy, and n-heptyloxy groups.
- any branched chain alkoxy group having 3 to 7 carbon atoms includes isopropoxy group, isobutyloxy group, tert-butyloxy group, isopentyloxy group and the like, and any cyclic group having 3 to 7 carbon atoms.
- Alkoxy groups include a cyclobutyloxy group, a cyclopentyloxy group, a cyclohexyloxy group, and the like.
- an aryl group having 3 to 12 carbon atoms which may contain a heteroatom refers to any aryl group having 6 to 12 carbon atoms, which is composed only of hydrocarbons, and Any heteroaryl group having 3 to 12 carbon atoms in which at least one carbon atom constituting the ring structure is replaced with a heteroatom (e.g., nitrogen atom, oxygen atom, sulfur atom, and combinations thereof) do.
- a heteroatom e.g., nitrogen atom, oxygen atom, sulfur atom, and combinations thereof
- the aryl group having 6 to 12 carbon atoms includes phenyl group, naphthyl group, indenyl group, azulenyl group and the like, and the arbitrary heteroaryl group having 3 to 12 carbon atoms includes pyridyl group, pyrrolyl group, quinolyl group, indolyl group, imidazolyl group, furyl group, thienyl group and the like.
- aralkyl group having an aryl moiety having 3 to 12 carbon atoms which may contain a heteroatom examples include a benzyl group, a phenethyl group, a naphthylmethyl group, a 3-phenylpropyl group, 2 -phenylpropyl group, 4-phenylbutyl group, 2-phenylbutyl group, pyridylmethyl group, indolylmethyl group, furylmethyl group, thienylmethyl group, pyrrolylmethyl group, 2-pyridylethyl group, 1-pyridylethyl group, 3 -thienylpropyl group and the like.
- acyl group examples include aliphatic acyl groups and aromatic acyl groups.
- examples of aliphatic acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl, isovaleryl, octanoyl, nonanoyl, decanoyl, 3-methylnonanoyl group, 8-methylnonanoyl group, 3-ethyloctanoyl group, 3,7-dimethyloctanoyl group, undecanoyl group, dodecanoyl group, tridecanoyl group, tetradecanoyl group, pentadecanoyl group, hexadecanoyl group, 1-methylpentadecanoyl group, 14-methylpentadecanoyl group, 13,13-dimethyltetradecanoyl group,
- aromatic acyl groups include arylcarbonyl groups such as benzoyl group, ⁇ -naphthoyl group and ⁇ -naphthoyl group; 2-bromobenzoyl group and halogenoarylcarbonyl group such as 4-chlorobenzoyl group; , 4,6-trimethylbenzoyl group, lower alkylated arylcarbonyl group such as 4-toluoyl group; lower alkoxylated arylcarbonyl group such as 4-anisoyl group; 2-carboxybenzoyl group, 3-carboxybenzoyl group, 4 -carboxylated arylcarbonyl group such as carboxybenzoyl group; nitrated arylcarbonyl group such as 4-nitrobenzoyl group and 2-nitrobenzoyl group; lower alkoxycarbonylated arylcarbonyl group such as 2-(methoxycarbonyl)benzoyl group group; an arylated aryl group
- sil group examples include a trimethylsilyl group, a triethylsilyl group, an isopropyldimethylsilyl group, a t-butyldimethylsilyl group, a methyldiisopropylsilyl group, a methyldi-t-butylsilyl group, and a triisopropylsilyl group.
- tri-lower alkylsilyl groups such as; tri-lower alkylsilyl groups substituted with 1 to 2 aryl groups such as diphenylmethylsilyl group, butyldiphenylbutylsilyl group, diphenylisopropylsilyl group and phenyldiisopropylsilyl group; mentioned.
- Trimethylsilyl group, triethylsilyl group, triisopropylsilyl group, t-butyldimethylsilyl group and t-butyldiphenylsilyl group are preferred, and trimethylsilyl group is more preferred.
- halogen atom includes, for example, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- a fluorine atom or a chlorine atom is preferred.
- halide ion includes, for example, fluoride ion, chloride ion, bromide ion, or iodide ion. Fluoride ions or chloride ions are preferred.
- protecting group for amino group for nucleic acid synthesis As used herein, the terms “protecting group for amino group for nucleic acid synthesis”, “protecting group for hydroxyl group for nucleic acid synthesis”, “hydroxyl group protected by protecting group for nucleic acid synthesis”, “protecting group for nucleic acid synthesis”
- the “protecting group” of "phosphate group” and “mercapto group protected by a protecting group for nucleic acid synthesis” is a group capable of stably protecting an amino group, hydroxyl group, phosphoric acid group or mercapto group during nucleic acid synthesis. If so, it is not particularly limited. Specifically, it refers to protective groups that are stable under acidic or neutral conditions and cleavable by chemical methods such as hydrogenolysis, hydrolysis, electrolysis, and photolysis.
- Such protecting groups include, for example, lower alkyl groups, lower alkenyl groups, acyl groups, tetrahydropyranyl or tetrahydrothiopyranyl groups, tetrahydrofuranyl or tetrahydrothiofuranyl groups, silyl groups, lower alkoxymethyl groups, lower alkoxy lower alkoxymethyl group, halogeno lower alkoxymethyl group, lower alkoxylated ethyl group, halogenated ethyl group, methyl group substituted with 1 to 3 aryl groups, "lower alkyl group, lower alkoxy group, halogen atom or cyano A methyl group substituted with 1 to 3 aryl groups substituted on an aryl ring with a group", a lower alkoxycarbonyl group, an "aryl group substituted with a halogen atom, a lower alkoxy group or a nitro group", a "halogen atom or A lower alkoxycarbonyl group substitute
- the tetrahydropyranyl group or tetrahydrothiopyranyl group includes a tetrahydropyran-2-yl group, a 3-bromotetrahydropyran-2-yl group, a 4-methoxytetrahydropyran-4-yl group and a tetrahydropyranyl group.
- a tetrahydrofuranyl group or a tetrahydrothiofuranyl group includes a tetrahydrofuran-2-yl group and a tetrahydrothiofuran-2-yl group.
- the lower alkoxymethyl group includes methoxymethyl group, 1,1-dimethyl-1-methoxymethyl group, ethoxymethyl group, propoxymethyl group, isopropoxymethyl group, butoxymethyl group, t-butoxymethyl group and the like.
- Lower alkoxylated lower alkoxymethyl groups include 2-methoxyethoxymethyl groups and the like.
- Halogeno lower alkoxymethyl groups include 2,2,2-trichloroethoxymethyl groups and bis(2-chloroethoxy)methyl groups.
- the lower alkoxylated ethyl group includes 1-ethoxyethyl group, 1-(isopropoxy)ethyl group and the like. Examples of halogenated ethyl groups include 2,2,2-trichloroethyl groups.
- the methyl group substituted with 1 to 3 aryl groups includes a benzyl group, ⁇ -naphthylmethyl group, ⁇ -naphthylmethyl group, diphenylmethyl group, triphenylmethyl group, ⁇ -naphthyldiphenylmethyl group, 9-an thrylmethyl group and the like.
- a methyl group substituted with 1 to 3 aryl groups whose aryl ring is substituted with a lower alkyl group, a lower alkoxy group, a halogen atom or a cyano group includes a 4-methylbenzyl group, a 2,4,6- trimethylbenzyl group, 3,4,5-trimethylbenzyl group, 4-methoxybenzyl group, 4-methoxyphenyldiphenylmethyl group, 4,4'-dimethoxytriphenylmethyl group, 2-nitrobenzyl group, 4-nitrobenzyl group , 4-chlorobenzyl group, 4-bromobenzyl group, 4-cyanobenzyl group and the like.
- lower alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl and isobutoxycarbonyl groups.
- the "aryl group substituted with a halogen atom, a lower alkoxy group or a nitro group” includes a 4-chlorophenyl group, a 2-fluorophenyl group, a 4-methoxyphenyl group, a 4-nitrophenyl group and a 2,4-dinitrophenyl group. etc.
- lower alkoxycarbonyl group substituted with a halogen atom or a tri-lower alkylsilyl group includes a 2,2,2-trichloroethoxycarbonyl group and a 2-trimethylsilylethoxycarbonyl group.
- alkenyloxycarbonyl groups include vinyloxycarbonyl groups and aryloxycarbonyl groups.
- the "aralkyloxycarbonyl group optionally substituted on the aryl ring with a lower alkoxy or nitro group” includes a benzyloxycarbonyl group, a 4-methoxybenzyloxycarbonyl group, a 3,4-dimethoxybenzyloxycarbonyl group, a 2-nitro benzyloxycarbonyl group, 4-nitrobenzyloxycarbonyl group and the like.
- Examples of the "lower alkoxycarbonyl group substituted with a cyano group” include a cyanoethoxycarbonyl group and the like.
- the "benzenesulfonyl group substituted with 1 to 4 nitro groups” includes a 2-nitrobenzenesulfonyl group, a 2,4-dinitrobenzenesulfonyl group and the like.
- the "hydroxyl-protecting group for nucleic acid synthesis” preferably includes an aliphatic acyl group, an aromatic acyl group, a methyl group substituted with 1 to 3 aryl groups, "lower alkyl, lower alkoxy, halogen, cyano a methyl group substituted with 1 to 3 aryl groups in which the aryl ring is substituted with a group, or a silyl group, more preferably an acetyl group, a benzoyl group, a benzyl group, a p-methoxybenzoyl group, a dimethoxy trityl group, monomethoxytrityl group or tert-butyldiphenylsilyl group.
- the protecting group for the "hydroxyl group protected by a protecting group for nucleic acid synthesis” is preferably an aliphatic acyl group, an aromatic acyl group, a "methyl group substituted with 1 to 3 aryl groups", a "halogen an aryl group substituted with an atom, a lower alkoxy group or a nitro group, a lower alkyl group or a lower alkenyl group, more preferably a benzoyl group, a benzyl group, a 2-chlorophenyl group, a 4-chlorophenyl group or a 2- It is a propenyl group.
- the “amino group-protecting group for nucleic acid synthesis” is preferably an acyl group, more preferably a benzoyl group.
- the "protecting group” of the "phosphate group protected by a protecting group for nucleic acid synthesis” is preferably a lower alkyl group, a lower alkyl group substituted with a cyano group, an aralkyl group, a "nitro group or a halogen atom an aralkyl group substituted with an aryl ring” or an "aryl group substituted with a lower alkyl group, a halogen atom, or a nitro group", more preferably a 2-cyanoethyl group or a 2,2,2-trichloroethyl group , benzyl group, 2-chlorophenyl group or 4-chlorophenyl group.
- protecting groups constituting "a phosphate group protected by a protecting group for nucleic acid synthesis".
- the "protecting group” of the "mercapto group protected by a protecting group for nucleic acid synthesis” is preferably an aliphatic acyl group or an aromatic acyl group, more preferably a benzoyl group.
- the "amino group-protecting group" for the R 10 group includes an acetyl group, a tertiary butoxycarbonyl (Boc) group, a 9-fluorenylmethyloxycarbonyl (Fmoc) group, and the like.
- —P(R 24 )R 25 [wherein R 24 and R 25 are each independently a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a mercapto group, a protecting group for nucleic acid synthesis A mercapto group, an amino group, a straight or branched chain alkoxy group having 1 to 6 carbon atoms, a straight or branched chain alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or carbon representing a linear or branched alkylamino group of numbers 1 to 6], the group in which R 24 can be represented as —OR 24a and R 25 can be represented as —N(R 25a ) 2 is represented by “ phosphoramidite group”.
- the phosphoramidite group is preferably a group represented by the formula -P(OC 2 H 4 CN)(N(iPr) 2 ), or a group represented by the formula -P(OCH 3 )(N(iPr) 2 ) and the group represented by
- iPr represents an isopropyl group.
- nucleoside includes “nucleosides” in which a purine or pyrimidine base and a sugar are attached, as well as aromatic heterocycles and aromatic hydrocarbon rings other than purines and pyrimidines that substitute for a purine or pyrimidine base. Includes “nucleosides” that are possible and sugar-linked. Natural nucleosides are also called “natural nucleosides”. Modified non-natural nucleosides are also referred to as “modified nucleosides”, and nucleotides with modified sugar moieties are particularly referred to as “sugar-modified nucleosides”. "Nucleotide” means a compound in which a phosphate group is attached to the sugar of a nucleoside.
- oligonucleotide refers to a polymer of “nucleotides” in which from 2 to 50 identical or different “nucleosides” are linked by phosphodiester or other linkages, naturally occurring and non-naturally occurring. Including those of type.
- the non-natural "oligonucleotide” preferably includes a sugar derivative with a modified sugar moiety; a thioate derivative with a thioated phosphodiester moiety; an ester with an esterified terminal phosphate moiety; Examples include amides in which the amino group on the base is amidated, and more preferably sugar derivatives in which the sugar moiety is modified.
- a salt thereof refers to a salt of the compound represented by formula (II) described below.
- Such salts include, for example, alkali metal salts such as sodium salts, potassium salts and lithium salts, alkaline earth metal salts such as calcium salts and magnesium salts, aluminum salts, iron salts, zinc salts, copper salts, Metal salts such as nickel salts and cobalt salts; inorganic salts such as ammonium salts, t-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucamine salts , guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benz
- the term "pharmacologically acceptable salt thereof” refers to a salt of an oligonucleotide containing at least one nucleoside structure represented by formula (I) shown below, wherein the oligonucleotide according to the present invention ie, salts that retain the desired biological activity of the oligonucleotide and do not impart undesired toxicological effects therein.
- Such salts include, for example, alkali metal salts such as sodium salts, potassium salts and lithium salts, alkaline earth metal salts such as calcium salts and magnesium salts, aluminum salts, iron salts, zinc salts, copper salts, Metal salts such as nickel salts and cobalt salts; inorganic salts such as ammonium salts, t-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucamine salts , guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzyl-phenethylamine salt, piperazine salt, tetramethylammonium salt, tris Amine
- oligonucleotide oligonucleotide
- the oligonucleotide of the present invention has the activity of inducing N exon skipping in the processing of REST pre-mRNA (REST pre-mRNA).
- REST pre-mRNA REST pre-mRNA
- Such oligonucleotides may be pharmacologically acceptable salts thereof.
- the nucleotide sequence information of the human REST gene is available from NCBI Reference Sequence: NG_029447.1 Homo sapiens RE1 silencing transcription factor (REST), RefSeqGene on chromosome 4.
- the base sequence of SEQ ID NO: 1 in the Sequence Listing corresponds to positions 24740 to 24789 of the human REST gene and spans the entire length of the N exon.
- the N exon is located between exons 3 and 4.
- the term "activity to induce N exon skipping in processing of REST pre-mRNA” means, for example, that an oligonucleotide binds to REST pre-mRNA, and then during processing of the pre-mRNA, Inducing skipping of the N exon, which promotes expression of REST and/or suppresses expression of the mutant sREST.
- the oligonucleotide is an antisense oligonucleotide (ASO) to the REST mRNA or pre-mRNA.
- This oligonucleotide is also called “splicing control oligonucleotide (SSO)" because it has the activity of inducing N exon skipping and thereby controls REST and sREST expression by pre-mRNA splicing.
- SSO splicing control oligonucleotide
- the activity of inducing N exon skipping can be determined by measuring the expression levels and expression ratios of REST and sREST by known methods (eg, reverse transcription-polymerase chain reaction (RT-PCR)). Oligonucleotides with N exon skipping activity can be concentration dependent, e.g. Activity can be determined by measuring the ratio (sREST/REST), or the ratio of REST to the "sum of REST and sREST" ("% exclusion") based on band intensity. The higher the skipping induction activity, the lower the "sREST/REST” and the higher the "%exclusion".
- RT-PCR reverse transcription-polymerase chain reaction
- “sREST/REST” is lower than when no antisense oligonucleotide is added (control), and when “sREST/REST” in the control is set to 1 (in other words, oligonucleotide "sREST/REST” is divided by the “sREST/REST” of the control), for example, 0.8 or less, preferably 0.7 or less, more preferably 0.6 or less, even more preferably 0.4 or less, and 0.2 It may be below.
- the "relative exon skipping activity” can be calculated by dividing the "% exclusion” of the oligonucleotide by the "% exclusion” of the control.
- the “relative exon skipping activity” is, for example, 1.2 or higher, preferably 1.4 or higher, more preferably 1.6 or higher, still more preferably 1.8 or higher, even if it is 2.0 or higher. good.
- an oligonucleotide "binds" to a REST pre-mRNA means that multiple different single-stranded oligonucleotides or nucleic acids can form two or more strands of nucleic acid due to nucleobase complementarity. Say. Preferably, it refers to the ability to form a double-stranded nucleic acid.
- the melting temperature (T m ) of a double-stranded or higher-stranded nucleic acid which is an index of thermal stability of binding, is not particularly limited.
- the melting temperature ( Tm ) of double - stranded nucleic acids can be determined, for example, as follows: , The oligonucleotide and the target RNA are mixed in equimolar amounts, heated at 95° C. for 5 minutes, then slowly cooled to room temperature for annealing to form a double-stranded nucleic acid.
- the change in absorbance (A) at 260 nm with temperature (T) was measured when the double-stranded nucleic acid was heated from 20°C to 95°C at a heating rate of 0.5°C/min.
- T is prepared, and the temperature at which the value of dA/dT in this graph becomes the largest, that is, the temperature at which the change in A due to T is the largest is taken as the Tm of the double-stranded nucleic acid.
- the melting temperature (T m ) is, for example, 40° C. or higher, preferably 50° C. or higher.
- complementary means that two different single-stranded oligonucleotides or nucleic acids are in a pairing relationship that allows them to form a double-stranded nucleic acid.
- the base sequences of the double-strand forming regions are completely complementary, but have one or several mismatches as long as they can form the double-stranded nucleic acid and have N exon skipping action.
- One or several mismatches means 1 to 4, preferably 1 to 3, more preferably 1 or 2 mismatches, depending on the length of the oligonucleotide.
- the oligonucleotide of the present invention is preferably 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more of the base sequence of the region forming the double strand or complete (100%) complementarity.
- Antisense oligonucleotides (ASO) that target REST genes are examples of oligonucleotides that have the activity of inducing N exon skipping in the processing (splicing) of REST mRNA precursors.
- Antisense oligonucleotides (ASOs) are capable of binding to target gene RNA (e.g., mRNA or pre-mRNA)/DNA, and have the activity of regulating the expression of the target gene (including splicing regulation), Refers to a single-stranded oligonucleotide that is complementary to the RNA (eg, mRNA or pre-mRNA)/DNA sequence of its target gene.
- Antisense oligonucleotides (ASO) in the present invention are "splicing control oligonucleotides (SSO)" in that they can regulate splicing of target genes.
- the oligonucleotide of the present invention can bind to a target region that is at least part of SEQ ID NO:1. Oligonucleotides of the invention may also bind to a target region that is at least part of SEQ ID NO:38 or 39.
- the sequences represented by SEQ ID NOs: 38 and 39 are both partial regions of SEQ ID NO: 1.
- a given "target region” refers to a region of the pre-mRNA shown in any of SEQ ID NOs: 1, 38 and 39, for example.
- the target region is preferably a region associated with the activity of inducing N exon skipping in REST.
- the target region is, for example, at least 12 bases long, e.g.
- a nucleic acid molecule or oligonucleotide "binds to a target region” means that the nucleic acid molecule or oligonucleotide does not necessarily form two or more strands (preferably double strands) with the entire target region, and the REST mRNA precursor It may form two or more strands (preferably two strands) with a region that is part of the target region, as long as it exhibits the activity of inducing skipping of the N exon in the processing of .
- the oligonucleotide having the activity of inducing skipping of the N exon of the REST pre-mRNA is, for example, complementary to the nucleotide sequence of the target region, which is at least part of SEQ ID NO: 1, and preferably has complete complementarity.
- Oligonucleotides e.g., antisense oligonucleotides
- Oligonucleotides of the invention are at least 12 bases long, e.g. 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 bases long. When the oligonucleotide has the above length, it can more effectively bind to the REST pre-mRNA and induce skipping of the N exon.
- Oligonucleotides for example, antisense oligonucleotides of the present invention are oligonucleotides that have the activity of inducing N exon skipping of REST pre-mRNA, and are, for example, It includes a sequence that is complementary to at least 12 bases.
- the oligonucleotide need not be entirely complementary to the target region consisting of the base sequence of SEQ ID NO: 1.
- a portion of the oligonucleotide may be a peripheral region (e.g., the 5' end and/or 3' end of the target region). 1-5 base extensions) (shown in SEQ ID NO: 2). The same is true for SEQ ID NOs:38 and 39.
- the design of the sequences of antisense oligonucleotides, such as the oligonucleotides (e.g., antisense oligonucleotides) of the present invention, based on the selected target region can be performed by methods commonly used by those skilled in the art.
- base sequences of antisense oligonucleotides include the sequences shown below (shown in the 5′ ⁇ 3′ direction) (the numbers in [] indicate the sequence targeted by the oligonucleotide, human REST
- the position of both ends of the sequence of SEQ ID NO: 1 in the pre-mRNA is represented by the base number at the 5' end of the sequence of SEQ ID NO: 1 being 1 and the number of bases in the direction of the 3' end being + (plus).
- the number of bases deviating from the end of the sequence of 1 is represented by a - (minus) value, and when simply represented by a numerical value of -, it is the number of bases from the 5' end. is the number of bases from the end.):
- aatggtatccatacccca (SEQ ID NO: 3) [+1/+18] accaaatggtatccatac (SEQ ID NO: 4) [+5/+22] taaatattaccaaatggt (SEQ ID NO: 5) [+13/+30] agtaaatattaccaaatg (SEQ ID NO: 6) [+15/+32] ctctagtaaatattacca (SEQ ID NO: 7) [+19/+36] cacactctagtaaattatt (SEQ ID NO: 8) [+23/+40] agatcacactctagtaaa (SEQ ID NO: 9) [+27/+44] atctagatcacactctag (SEQ ID NO: 10) [+31/+48] acccatctagatcacact (SEQ ID NO: 11) [+35/-2(3')]
- Atcacactctagtaaattatt (SEQ ID NO: 40) [+23/+42] cacactctagtaaatattac (SEQ ID NO: 41) [+21/+40] cactctagtaaattatt (SEQ ID NO: 42) [+23/+38] cacactctagtaaata (SEQ ID NO: 43) [+25/+40] ctagatcacactctagtaaa (SEQ ID NO: 44) [+27/+46] agatcacactctagtaaata (SEQ ID NO: 45) [+25/+44] atcacactctagtaaa (SEQ ID NO: 46) [+27/+42] agatcacactctagta (SEQ ID NO: 47) [+29/+44] agatcacactctagtaaattatt (SEQ ID NO: 48) [+23/+44] gatcacactctagtaaat (SEQ ID
- the added base is complementary to the base of the sequence shown in SEQ ID NO: 2 (showing the base sequence of the target region and the adjacent region) adjacent to the target region (SEQ ID NO: 1) of the sequence to which the base is added. It can be a base.
- the oligonucleotides of the present invention include both oligonucleotides containing natural DNA (unmodified oligonucleotides) and oligonucleotides containing chemically modified DNA. Such modifications may alter the activity of the oligonucleotide, eg, increase its affinity for a target nucleic acid, or increase its resistance to nucleases. Increasing the affinity of the oligonucleotide for its target may allow the use of shorter oligonucleotides.
- the oligonucleotide according to the present invention may contain at least one sugar-modified nucleoside at any position.
- the ratio of the number of sugar-modified nucleotides to all nucleosides constituting the oligonucleotide is, for example, 30% or more, preferably 40% or more, and more preferably 50% or more.
- the sugar-modified nucleoside has a bridging moiety between the 2' and 4' positions of the sugar ring, eg, as described below.
- the oligonucleotide of the present invention contains at least one nucleoside structure represented by the following formula (I) as a sugar-modified nucleoside:
- Base is a purin-9-yl group optionally having one or more arbitrary substituents selected from the ⁇ group, or optionally having one or more arbitrary substituents selected from the ⁇ group 2 -oxo-1,2-dihydropyrimidin-1-yl group, wherein the ⁇ group is a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a linear alkyl group having 1 to 6 carbon atoms, a carbon linear alkoxy group of number 1 to 6, mercapto group, mercapto group protected by protecting group for nucleic acid synthesis, linear alkylthio group of 1 to 6 carbon atoms, amino group, linear alkylamino group of 1 to 6 carbon atoms , an amino group protected by a protective group for nucleic acid synthesis, and a halogen atom,
- A is:
- R 1 is selected from a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, an optionally branched or ring-forming alkenyl group having 2 to 7 carbon atoms, and the ⁇ group an aryl group having 3 to 12 carbon atoms which may have one or more optional substituents and may contain a heteroatom, and one or more optional substituents selected from the ⁇ group represents an aralkyl group having an aryl moiety of 3 to 12 carbon atoms which may optionally contain a heteroatom, or an amino group-protecting group for nucleic acid synthesis;
- R 2 and R 3 are each independently a hydrogen atom; optionally substituted with an aryl group having 3 to 12 carbon atoms which may contain a heteroatom, and optionally branched or forming a ring; an alkyl group having 1 to 7 carbon atoms; or an aralkyl group having an aryl moiety having 3 to 12 carbon
- R 17 , R 18 and R 19 each independently form a hydrogen atom, a branch or a ring an alkyl group having 1 to 7 carbon atoms, an amino group-protecting group, or
- R 13 and R 14 each independently represents a hydrogen atom; a hydroxyl group; an alkyl group having 1 to 7 carbon atoms which may be branched or forming a ring; A group selected from the group consisting of an alkoxy group of 7; an amino group; and an amino group protected by a protecting group for nucleic acid synthesis; m is an integer from 0 to 2; n is an integer from 0 to 1; R 10 is a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, an amino-protecting group, or
- R 15 and R 16 are each independently a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, or an amino group-protecting group. ,or
- X is an oxygen atom, a sulfur atom, or an amino group
- Y is an oxygen atom or a sulfur atom.
- nucleoside structure represented by formula (I) above is
- R 1 is a hydrogen atom, an alkyl group having 1 to 7 carbon atoms which may form a branch or a ring, or may form a branch or a ring.
- It is an aralkyl group having an aryl moiety of 3 to 12 carbon atoms which may have one or more optional substituents selected from the group and which may contain a heteroatom.
- R 1 is a hydrogen atom, methyl group, ethyl group, n-propyl group, isopropyl group, phenyl group, or benzyl group, and even more preferably R 1 is a hydrogen atom or a methyl group. be.
- n is an integer from 0 to 1.
- the ring including the 2'-positions, 3'-positions, 4'-positions, and the bridging moiety may constitute a 5- to 7-membered ring.
- X is an oxygen atom, a sulfur atom, an amino group, or a methylene group.
- X is an oxygen atom or an amino group.
- X when X is an amino group or a methylene group, it may be substituted with a lower alkyl group.
- the nucleoside structure represented by formula (I) above is a structure represented by formula (I-1) above, and in formula (I-1) m is 0; and R 1 is a hydrogen atom, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a phenyl group, or a benzyl group.
- Nucleoside structures represented by formula (I) above include, in addition to formulas (I-1) and (I-2) above, for example, the following (I-3) to (I-7):
- R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 , R 14 , R 15 , R 16 and p are As described above with respect to formula (I).
- Formula (I-7) is referred to as 2',4'-BNA or LNA (Locked Nucleic Acid) (also referred to herein as "2',4'-BNA/LNA” or "LNA”). (for example, both R 13 and R 14 are hydrogen atoms).
- Formula (I-3) has a structure in which a spirocyclopropane group is introduced at the 6' position of the 2',4'-BNA/LNA crosslinked portion, and is also referred to as spirocyclopropane crosslinked nucleic acid (spcBNA).
- Formula (I-4) has a structure in which guanidine is introduced into the crosslinked portion of 2',4'-BNA/LNA, and is also called guanidine-bridged nucleic acid (GuNA).
- Base is a purine base (ie, purine-9-yl group) or a pyrimidine base (ie, 2-oxo-1,2-dihydropyrimidin-1-yl group).
- bases include a hydroxyl group, a linear alkyl group having 1 to 6 carbon atoms, a linear alkoxy group having 1 to 6 carbon atoms, a mercapto group, a linear alkylthio group having 1 to 6 carbon atoms, an amino group, and a 6 linear alkylamino groups and one or more optional substituents selected from the ⁇ group consisting of halogen atoms.
- Base examples include an adenynyl group, a guanynyl group, a cytosinyl group, a uracilyl group, a thyminyl group, a 6-aminopurin-9-yl group, a 2,6-diaminopurin-9-yl group, a 2 -amino-6-chloropurin-9-yl group, 2-amino-6-fluoropurin-9-yl group, 2-amino-6-bromopurin-9-yl group, 2-amino-6-hydroxypurine- 9-yl group, 6-amino-2-methoxypurin-9-yl group, 6-amino-2-chloropurin-9-yl group, 6-amino-2-fluoropurin-9-yl group, 2,6 -dimethoxypurin-9-yl group, 2,6-dichloropurin-9-yl group, 6-mercaptopurin-9-yl group
- Base has the following structural formula from the perspective of introduction into nucleic acid medicine:
- thyminyl group cytosinyl group, adenynyl group, guanynyl group, 5-methylcytosinyl group and uracilyl group
- 2-oxo-4-hydroxy-5-methyl-1,2-dihydropyrimidin-1-yl and thyminyl groups are preferred
- the oligonucleotide according to the present invention has a nucleoside structure represented by the above formula (I-4), formula (I-4-1) or formula (I-4-2) as a sugar-modified nucleoside.
- these nucleoside structures represented by formula (I-4) or formula (I-4-1) or formula (I-4-2) are represented by formula (I-4) or formula (I-4- 1) or is held electrically neutral by a pharmaceutically acceptable anion not represented in formula (I-4-2) (which can be represented as, for example, Z 1 ⁇ ).
- examples of such anions include halide ions (eg, chloride ions), phosphate ions, and the like.
- a sugar-modified nucleoside compound for example, WO 2011/052436, JP 2014-043462, WO 2014/ 046212 and WO2015/125783.
- sugar-modified nucleoside compounds include compounds represented by the following formula (II) or salts thereof:
- Base is a purin-9-yl group optionally having one or more arbitrary substituents selected from the ⁇ group, or optionally having one or more arbitrary substituents selected from the ⁇ group 2 -oxo-1,2-dihydropyrimidin-1-yl group, wherein the ⁇ group is a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a linear alkyl group having 1 to 6 carbon atoms, a carbon linear alkoxy group of number 1 to 6, mercapto group, mercapto group protected by protecting group for nucleic acid synthesis, linear alkylthio group of 1 to 6 carbon atoms, amino group, linear alkylamino group of 1 to 6 carbon atoms , an amino group protected by a protective group for nucleic acid synthesis, and a halogen atom,
- A is:
- R 1 is selected from a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, an optionally branched or ring-forming alkenyl group having 2 to 7 carbon atoms, and the ⁇ group an aryl group having 3 to 12 carbon atoms which may have one or more optional substituents and may contain a heteroatom, and one or more optional substituents selected from the ⁇ group represents an aralkyl group having an aryl moiety of 3 to 12 carbon atoms which may optionally contain a heteroatom, or an amino group-protecting group for nucleic acid synthesis;
- R 2 and R 3 are each independently a hydrogen atom; optionally substituted with an aryl group having 3 to 12 carbon atoms which may contain a heteroatom, and optionally branched or forming a ring; an alkyl group having 1 to 7 carbon atoms; or an aralkyl group having an aryl moiety having 3 to 12 carbon
- R 17 , R 18 and R 19 each independently form a hydrogen atom, a branch or a ring an alkyl group having 1 to 7 carbon atoms, an amino group-protecting group, or
- R 13 and R 14 each independently represents a hydrogen atom; a hydroxyl group; an alkyl group having 1 to 7 carbon atoms which may be branched or forming a ring; A group selected from the group consisting of an alkoxy group of 7; an amino group; and an amino group protected by a protecting group for nucleic acid synthesis; m is an integer from 0 to 2; n is an integer from 0 to 1;
- R 10 is a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, an amino-protecting group, or
- R 15 and R 16 are each independently a hydrogen atom, an optionally branched or ring-forming alkyl group having 1 to 7 carbon atoms, or an amino group-protecting group. ,or
- R 22 and R 23 are each independently a hydrogen atom, a hydroxyl-protecting group for nucleic acid synthesis, or a C 1-7 group which may form a branch or ring.
- Sugar-modified nucleotides can be easily prepared from the above sugar-modified nucleosides.
- triphosphorylation can be readily performed according to the method described in M. Kuwahara et al., Nucleic Acids Res., 2008, vol.36, No.13, pp.4257-65.
- Phosphate modifications include, for example, phosphodiester bonds of natural nucleic acids, S-oligo (phosphorothioate), D-oligo (phosphodiester), M-oligo (methylphosphonate), boranophosphate, and the like.
- S-oligo(phosphorothioates) have a PS backbone in which the oxygen atoms in the phosphate groups of the internucleoside phosphodiester linkages are replaced by sulfur atoms. This modification is incorporated into the oligonucleotide according to known methods.
- An antisense oligonucleotide having one or more such modifications in the oligonucleotide is also called an S-oligo type (phosphorothioate type).
- Nucleobase modifications include, for example, 5-methylcytosine, 5-hydroxymethylcytosine, 5-propynylcytosine and the like.
- the position and number of sugar-modified nucleosides are not particularly limited, and can be appropriately designed according to the purpose. Two or more sugar-modified nucleosides include, for example, the same or different from each other. Oligonucleotides can be designed with sugar-modified and unmodified nucleosides alternating. For oligonucleotides of the invention, it is preferred that a region consisting of 1-3 residues of unmodified nucleosides is followed by sugar-modified nucleosides. This makes the RNA to which the oligonucleotide binds difficult to be cleaved via RNase H.
- nucleoside structure represented by formula (I) above is
- R 1 is a hydrogen atom, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a phenyl group, or a benzyl group).
- the oligonucleotide of the present invention comprises a base sequence represented by any of the base sequences of SEQ ID NOS: 3-11 and SEQ ID NOS: 40-49, and at least one of the bases is the above sugar.
- Oligonucleotides that are modified nucleosides include, for example, those shown below:
- the numbers in [] indicate the target sequence of the oligonucleotide, with the 5′ terminal base of the sequence of SEQ ID NO: 1 in human REST pre-mRNA being 1, 3 It is represented by the positions of both ends when the number of bases in the direction of the 'terminal side is regarded as + (plus).
- the number of bases deviating from the end of the sequence of SEQ ID NO: 1 is represented by a - (minus) value, and when simply represented by a numerical value of -, it is the number of bases from the 5' end, and is described as (3') together with the - value. In case, it is the number of bases from the 3' end.
- Oligonucleotides in the present invention can be synthesized by conventional methods using sugar-modified nucleosides and natural nucleosides as described above. can be easily synthesized by manufacturing, etc.). Synthetic methods include a solid-phase synthesis method using phosphoramidite, a solid-phase synthesis method using hydrogenphosphonate, and the like. For example, disclosed in Tetrahedron Letters, 1981, vol.
- the pharmaceutical composition of the present invention contains the above oligonucleotide or a pharmacologically acceptable salt thereof.
- the pharmaceutical composition of the present invention is useful, for example, for treating or preventing diseases involving REST processing (splicing).
- Target diseases of the pharmaceutical composition of the present invention include, for example, cancer diseases and heart failure.
- Cancer diseases associated with REST processing include, for example, SRRM4-mediated cancers (eg, small cell lung cancer, prostate cancer (eg, castration-resistant prostate cancer (CRPC)), breast cancer). Such cancer diseases may originate from neuroendocrine cells.
- the present invention encompasses a therapeutic agent for cancer containing the above oligonucleotide or a pharmacologically acceptable salt thereof.
- the present invention also includes a therapeutic agent for heart failure containing the above oligonucleotide or a pharmacologically acceptable salt thereof.
- the administration method and formulation of the pharmaceutical composition of the present invention or the drug for treating cancer or the drug for treating heart failure may be any administration method and formulation known in the art. Available.
- compositions, etc. of the present invention can be administered locally or systemically or by various methods depending on the region to be treated.
- Methods of administration may be, for example, topical (including, for example, eye drops, intravaginal, intrarectal, intranasal and transdermal), oral, or parenteral.
- Parenteral administration includes intravenous injection or infusion, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration through the respiratory tract by inhalation or inhalation, and the like.
- formulations such as transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders can be used.
- compositions for oral administration include powders, granules, suspensions or solutions dissolved in water or non-aqueous media, capsules, powders, tablets and the like.
- compositions for parenteral administration include sterile aqueous solutions containing buffers, diluents and other suitable additives.
- the pharmaceutical composition, etc. of the present invention contains an effective amount of the above-mentioned oligonucleotide or a pharmacologically acceptable salt thereof and excipients, binders, wetting agents, disintegrants, lubricants, and diluents suitable for the dosage form. It can be obtained by mixing various pharmaceutical additives such as, if necessary. In the case of an injection, it may be sterilized with an appropriate carrier to form a preparation.
- the present invention provides a method of inducing N exon skipping during REST processing.
- the present invention also provides methods for the treatment or prevention of diseases involving REST processing. In one embodiment, these methods are used to treat or prevent the target diseases described above. These methods comprise administering to an individual the oligonucleotides described above or pharmacologically acceptable salts thereof.
- "Individuals" are preferably mammals, more preferably humans, monkeys, dogs, cats, rats and mice, and even more preferably humans. In these methods, the administration method and dosage form are not limited as long as an effective dose of the oligonucleotide of the present invention is administered.
- the effective dose depends on the individual to be administered, it can be arbitrarily determined according to the individual's sex, age, body weight, symptoms, etc., as well as the administration method, route, frequency, and the like.
- the administration method and the like are as described above.
- Example 1 Antisense oligonucleotide synthesis
- Oligonucleotides related to the present invention were synthesized by the method described in Tetrahedron Letters 22, 1859-1862 (1981), International Publication No. 2011/052436, and the like. Based on the design in Example 1, an oligonucleotide containing an amide BNA (AmNA) represented by the following formula was synthesized with reference to the method described in WO 2011/052436:
- AmNA amide BNA
- Base is a 5-methylcytosinyl group, thyminyl group, adenynyl group or guanynyl group, and Me is a methyl group.
- An 18-mer oligonucleotide containing amide BNA (AmNA) was synthesized on a 0.2 ⁇ mol scale using an automatic nucleic acid synthesizer (nS-8 type, manufactured by Gene Design Co., Ltd.). Chain length extension was performed using standard phosphoramidite protocols (solid support: CPG resin, sulfurization for phosphorothioated (PS) backbone formation was performed using DDT (3H-1,2-benzodisiol-3-one, 1, 1-dioxide), etc.) to obtain an oligonucleotide in which the hydroxyl group at the terminal 5'-position was protected with a DMTr (dimethoxytrityl) group and the 3'-position was supported on a solid phase.
- DMTr dimethyl methoxytrityl
- the desired product was cleaved from the solid phase carrier by base treatment. After neutralization with dilute acid, the solvent was distilled off, and the resulting crude product was purified by gel filtration column chromatography and reversed-phase HPLC to obtain the desired product.
- Antisense oligonucleotides were designed to target the pre-mRNA of the human REST gene (NCBI Reference Sequence: NG_029447.1 Homo sapiens RE1 silencing transcription factor (REST), RefSeqGene on chromosome 4.).
- the reverse sequences (CG, GGA, GCA) of CG, TCC, and TGC that express toxicity in antisense were excluded.
- regions such as loop structures that are easily accessible to antisense oligonucleotides were selected.
- Blast was used to allow human application based on the results evaluated in mice.
- the regions of REST pre-mRNA that are highly homologous to humans and mice were selected.
- 18 candidate sequences were selected.
- An oligonucleotide consisting of a base sequence complementary to the candidate sequence selected as described above was designed as an antisense oligonucleotide.
- the antisense oligonucleotides were 18-mers in length, and the 5' end was designed to alternate artificial nucleic acids and DNA as artificial nucleic acids (AmNA) containing sugar-modified nucleosides.
- AmNA artificial nucleic acids
- the numerical value in [] indicates the target sequence of the oligonucleotide, and the 5' terminal base of the sequence of SEQ ID NO: 1 in human REST pre-mRNA is 1, and the 3' It is represented by the position of both ends when the number of bases in the terminal side direction is regarded as + (plus).
- the number of bases deviating from the end of the sequence of SEQ ID NO: 1 is represented by a - (minus) value, and when simply represented by a numerical value of -, it is the number of bases from the 5' end, and is described as (3') together with the - value. In case, it is the number of bases from the 3' end.
- Phosphorothioate refers to a structure in which the oxygen atom of the phosphate group in the phosphodiester bond is substituted with a sulfur atom (the group corresponding to the phosphate group is called a phosphorothioate group).
- an oligonucleotide in which all phosphate groups of the oligonucleotide are replaced with phosphorothioate groups is particularly referred to as an S-oligonucleotide.
- Example 3 Evaluation of antisense oligonucleotide splicing control (N exon skipping) effect in SCLC cells
- STC1 human SCLC cells
- test oligonucleotide 1.0 nmol
- STC1 cells 1.0 ⁇ 10 6 cells
- Sterile water was used as a control (mock).
- SRRM4 which is aberrantly expressed in SCLC cells, is also expressed in endocrine prostate cancer (NEPC). Therefore, in order to further expand the indication, we evaluated a prostate cancer cell line (VCaP) that has been confirmed to express SRRM4.
- test oligonucleotides were introduced by the lipofection method. After 48 hours, the cells were collected and analyzed according to standard methods. The sREST/REST expression ratio was determined in the same manner as in Example 3, and the splicing control (N exon skipping) effect of these antisense oligonucleotides was evaluated.
- splicing control (N exon skipping) effect by oligonucleotides was confirmed not only in SCLC cells but also in VCaP cells.
- Antisense oligonucleotides for which splicing control effects have been confirmed are referred to as splicing control oligonucleotides (SSO).
- SSO splicing control oligonucleotide
- AmNA_[+31/+48] 0.1, 1.0, 2.0 nmol
- control AmNA_26 were introduced into H146 cells (1.0 ⁇ 10 6 cells) by electroporation, and the cells were harvested after 96 hours.
- control AmNA_26 (0.1, 1.0 nmol) did not change the REST band in H146 cells (1.0 ⁇ 10 6 cells), but AmNA_[+31/+48] reduced sREST. and the intensity of the REST band increased (Fig. 3A).
- Example 6 Concentration-dependent evaluation of REST splicing control of splicing control oligonucleotides (SSO)
- SSO splicing control oligonucleotides
- test oligonucleotides 2.5 nM, 5 nM, 10 nM
- VCaP cells 1.0 ⁇ 10 6 cells
- Example 7 Concentration-dependent evaluation of REST splicing control of splicing control oligonucleotide (SSO) 2
- SSO splicing control oligonucleotide
- test oligonucleotides 2.5 nM, 5 nM, 10 nM
- VCaP cells 1.0 ⁇ 10 5 cells
- Example 8 Concentration-dependent evaluation of REST splicing regulation of splicing control oligonucleotides (AmNA[+23/+40] and AmNA[+27/+44])
- AmNA[+23/+40] and AmNA[+27/+44] which were shown to have high relative exon skipping activity in Example 7, the splicing control effect was verified by finely varying the concentrations.
- the above SSO was added to prostate cancer cells (VCaP) at various concentrations, and the expression of REST and sREST in vitro was examined by RT-PCR to determine "% exclusion" and determine the splicing control (N exon skipping) effect. evaluated.
- Test oligonucleotides (0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM) were introduced into VCaP cells (1.0 x 10 5 cells) by the lipofection method. Analysis was performed based on Sterile water was used as a control (mock).
- Example 9 EC50 analysis of splicing control oligonucleotides (AmNA[+23/+40] and AmNA[+27/+44])
- AmNA_2340 AmNA[+27/+44]
- AmNA_2744 AmNA[+27/+44]
- Test oligonucleotides (0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM) were introduced into VCaP cells (1.0 x 10 5 cells) by the lipofection method. Analysis was performed based on The 'relative exon skipping activity' at each concentration was calculated, plotted on a graph and curve regression was performed.
- Example 10 Optimization study of splicing control oligonucleotide (SSO)) Based on AmNA[+23/+40] (AmNA_2340) and AmNA[+27/+44] (AmNA_2744), which were shown to have high relative exon skipping activity in Example 7, the sequence length was changed, AmNA We examined the optimization of SSO by exchanging the positions of natural nucleic acids and/or changing the number of introduced AmNAs.
- Fig. 8 shows an overview of the sequence length of the SSO that was studied. In addition, SSO as a negative control was also examined. Four scrambled sequences were designed (Table 1) without changing the ATGC ratio of AmNA [+35/-2] and the rate of artificial nucleic acid introduction (for each base).
- the above SSO was added to prostate cancer cells (VCaP) at a concentration of 1.0 nM, and the expression of REST and sREST in vitro was examined by RT-PCR to determine "% exclusion” and splicing control (N exon skipping) effect. evaluated. Sterilized water was used as a control (mock), and NC3 was used as a control (NC).
- Example 11 REST splicing control evaluation of splicing control oligonucleotides (SSO) in 22Rv1 cells
- AmNA[+23/+40] AmNA_2340
- AmNA[+27/+44] AmNA_2744
- AmNA[+21/+40] AmNA_2140
- AmNA[ +23/+44] was verified whether it has similar splicing regulatory effects in different cell types.
- the cells used in this example are 22Rv1, a human prostate cancer epithelial cell line derived from serially grown xenografts in mice.
- the above SSO was added to prostate cancer cells (22Rv1) at a concentration of 1.0 nM, and the expression of REST and sREST in vitro was examined by RT-PCR to determine "% exclusion” and splicing control (N exon skipping) effect. evaluated.
- 22Rv1 cells (1.0 ⁇ 10 5 cells) were transfected with the test oligonucleotide (1.0 nM) by lipofection, and 48 hours later, the cells were collected and analyzed according to standard methods. Sterilized water was used as a control (mock), and NC3 was used as a control (NC).
- Example 12 Verification of the effect of splicing control oligonucleotide (SSO) on SRRM4 gene expression
- SSO splicing control oligonucleotide
- the SRRM4 gene has an RE1 sequence whose expression is controlled by REST, and high expression of REST suppresses SRRM4 gene expression.
- the SRRM4 protein is a protein that controls the splicing of REST pre-mRNA, and it is known that the SRRM4 protein highly expresses sREST in SCLC (Fig. 15).
- test oligonucleotide 1.0 nM
- 22Rv1 cells 1.0 ⁇ 10 5 cells
- a control no SSO added
- the expression level of SRRM4 mRNA was measured. Sterilized water was used as a control (mock), and NC3 was used as a control (NC).
- Example 13 Evaluation of antitumor effect in vivo
- AmNA_2140 which has a high splicing effect and an SRRM4 mRNA expression-suppressing effect, exerts an antitumor effect in vivo.
- Physiological saline was used as a control.
- SCLC cells (cell culture) Cell lines were purchased from the American Type Culture Collection (ATCC). SCLC cells (H146, H209) were cultured as floating cells, and prostate cancer cells (VCaP, 22Rv1) as adherent cells.
- the medium was RPMI-1640 (containing 4,500 mg/l glucose, L-glutamine, phenol red, HEPES, sodium pyruvate: Ref 187-02705: LOT ESH7003) and FBS (Gibco TM fetal bovine serum, qualified, Brazil: Ref 10270106: LOT 42F0288K) was added to 10%.
- the inside of the incubator was 37°C and 5% CO 2 .
- the cell lines used are as follows. SCLC cell lines: H146 (HTB-173), H209 (HTB-172), prostate cancer cell lines: VCaP (CRL-2876), 22Rv1 (CRL-2505)
- SRRM4 expression analysis by qRT-PCR 0.5 ⁇ 10 6 cells were seeded in 6-well plates with 1750 ⁇ l of RPMI-1640 24 hours before transfection. 7.5 ⁇ l/well of Lipofectamine TM 3000 (manufactured by Thermo Fisher Scientific) and 250 ⁇ l of a complex solution of SRRM4-ASO and Lipofectamine TM 3000 Reagent prepared according to the package insert for other items were added to each well. For 24-well plates, 0.1 ⁇ 10 6 cells were seeded with 450 ⁇ l of RPMI-1640 24 hours before transfection.
- Lipofectamine TM 3000 (manufactured by Thermo Fisher Scientific) was added to each well at 1.5 ⁇ L/well, and 50 ⁇ L of the complex solution obtained according to the package insert for other items was added to each well.
- 5.0 ⁇ 10 4 cells were seeded in 100 ⁇ l of RPMI-1640 in 96-well plates 24 hours before transfection.
- 0.3 ⁇ l/well of Lipofectamine TM 3000 manufactured by Thermo Fisher Scientific
- 10 ⁇ l of a complex solution of SRRM4-ASO and Lipofectamine TM 3000 prepared according to the manufacturer's instructions were added to each well.
- Total RNA extraction/cDNA synthesis Total RNA was extracted using RNeasy Plus Micro Kit (Qiagen) according to the package insert. Total RNA was quantified spectrophotometrically at 260 nm, adjusted with RNase-free water to 100 ng/16 ⁇ l, then 4 ⁇ l of SuperScript VILO (manufactured by Thermo Fischer Scientific) was added for reverse transcription (42°C, 60 minutes). ) was implemented.
- Quantitative PCR was performed using StepOnePlus TM Real-Time PCR Systems (Thermo Fisher Scientific). A master mix was prepared using TaqMan TM Fast Advanced Master Mix (manufactured by Thermo Fisher Scientific). For SRRM4, each primer was prepared at 10 pmol in a 20 ⁇ l reaction. ⁇ -actin was prepared according to the package insert of TaqMan TM ⁇ -Actin Detection Reagents (manufactured by Thermo Fisher Scientific). 1/100 of the cDNA obtained from the reverse transcription reaction was analyzed by qRT-PCR. The reaction conditions were 40 cycles of 95° C. for 20 seconds, 95° C. for 3 seconds, and 60° C. for 30 seconds.
- RNA expression analysis by RT-PCR method 1/10 of the cDNA obtained from the RT reaction was amplified using Hot Start Taq DNA polymerase (New England Biolabs). The reaction conditions were 95°C for 30 seconds, 95°C for 15 seconds, 58°C for 15 seconds, and 68°C for 30 seconds for 20 cycles for ⁇ -actin, 35 cycles for REST and sREST, followed by 2 cycles at 68°C. minutes. Each primer was prepared at 5 pmol each in a 25 ⁇ L reaction solution. PCR products were subjected to electrophoresis using 5% Mini-PROTEAN TBE Precast Gels (BIO RAD). As the electrophoresis buffer, 10 ⁇ Tris-Borate-EDTA Buffer (manufactured by Nacalai Tesque, Inc.) was diluted 0.5 times and used.
- Mini-PROTEAN Tetra System (BIO RAD) was used as the electrophoresis apparatus.
- the I Bright FL1500 Imaging System was used for gel photography and band quantification. A value representing the brightness of the band per unit area was quantified from the image using the function of the I Bright FL1500 Imaging System, and the REST value with respect to the sum of the sREST and REST values was used as an evaluation index. This value is shown in Figure 3B as %exclusion.
- the primer sequences were as follows: REST For. Primer: 5'-gaacgcccatataaatgtgaa-3' (SEQ ID NO: 33); REST Rev.
- Primer 5'-tttgaagttgcttctatctgctgt-3' (SEQ ID NO: 34); ⁇ -actin For.Primer: 5′-ggccgtcttccctccatcg-3′ (SEQ ID NO: 35); ⁇ -actin Rev. Primer: 5′-ccagttggtgacgatgccgtgc-3′ (SEQ ID NO: 36)
- Example 9 The data obtained in Example 9 were introduced into graphing software GraphPad Prism, curve regression was performed by 4 Parameter Logistic ( 4PL ), and EC50 was calculated.
- the present invention is useful, for example, in the production of pharmaceuticals for treating cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Baseは、α群から選択される任意の置換基を1以上有していてもよいプリン-9-イル基、またはα群から選択される任意の置換基を1以上有していてもよい2-オキソ-1,2-ジヒドロピリミジン-1-イル基を表し、ここで、該α群は、水酸基、核酸合成の保護基で保護された水酸基、炭素数1から6の直鎖アルキル基、炭素数1から6の直鎖アルコキシ基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、炭素数1から6の直鎖アルキルチオ基、アミノ基、炭素数1から6の直鎖アルキルアミノ基、核酸合成の保護基で保護されたアミノ基、およびハロゲン原子からなり、
Aは、以下:
R1は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数2から7のアルケニル基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基、または核酸合成のアミノ基の保護基を表し;
R2およびR3は、それぞれ独立して、水素原子;ヘテロ原子を含んでいてもよい炭素数3から12のアリール基で置換されていてもよく、かつ分岐または環を形成していてもよい炭素数1から7のアルキル基;またはヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基;であるか、あるいは
R2およびR3は一緒になって、-(CH2)q-[式中、qは2から5の整数である]を表し;
R4およびR5は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であるか、あるいは、R4およびR5は一緒になって、=C(R11)R12[式中、R11およびR12は、それぞれ独立して、水素原子、水酸基、核酸合成の保護基で保護された水酸基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、アミノ基、炭素数1から6の直鎖または分岐鎖アルコキシ基、炭素数1から6の直鎖または分岐鎖アルキルチオ基、炭素数1から6のシアノアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルアミノ基を表す]であり;
R6およびR7は、それぞれ独立して、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基であり;
R8は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基を表し;
R9は、水素原子、水酸基、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、アミノ基、あるいは核酸合成の保護基で保護されたアミノ基であり;
R10は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
R13およびR14は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であり;
mは、0から2の整数であり;
nは、0から1の整数であり;
R10が水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
R10が-(C=(NHR17)+)-NR18R19である場合、pは0であり;
Xは、酸素原子、硫黄原子、またはアミノ基であり;そして
Yは酸素原子または硫黄原子である)
の少なくとも1つを含む。
で表される。
まず、本明細書中で用いられる用語を定義する。
以下、本発明について詳述する。
accaaatggtatccatac(配列番号4)[+5/+22]
taaatattaccaaatggt(配列番号5)[+13/+30]
agtaaatattaccaaatg(配列番号6)[+15/+32]
ctctagtaaatattacca(配列番号7)[+19/+36]
cacactctagtaaatatt(配列番号8)[+23/+40]
agatcacactctagtaaa(配列番号9)[+27/+44]
atctagatcacactctag(配列番号10)[+31/+48]
acccatctagatcacact(配列番号11)[+35/-2(3’)]
cacactctagtaaatattac(配列番号41)[+21/+40]
cactctagtaaatatt(配列番号42)[+23/+38]
cacactctagtaaata(配列番号43)[+25/+40]
ctagatcacactctagtaaa(配列番号44)[+27/+46]
agatcacactctagtaaata(配列番号45)[+25/+44]
atcacactctagtaaa(配列番号46)[+27/+42]
agatcacactctagta(配列番号47)[+29/+44]
agatcacactctagtaaatatt(配列番号48)[+23/+44]
gatcacactctagtaaat(配列番号49)[+26/+43]
Baseは、α群から選択される任意の置換基を1以上有していてもよいプリン-9-イル基、またはα群から選択される任意の置換基を1以上有していてもよい2-オキソ-1,2-ジヒドロピリミジン-1-イル基を表し、ここで、該α群は、水酸基、核酸合成の保護基で保護された水酸基、炭素数1から6の直鎖アルキル基、炭素数1から6の直鎖アルコキシ基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、炭素数1から6の直鎖アルキルチオ基、アミノ基、炭素数1から6の直鎖アルキルアミノ基、核酸合成の保護基で保護されたアミノ基、およびハロゲン原子からなり、
Aは、以下:
R1は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数2から7のアルケニル基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基、または核酸合成のアミノ基の保護基を表し;
R2およびR3は、それぞれ独立して、水素原子;ヘテロ原子を含んでいてもよい炭素数3から12のアリール基で置換されていてもよく、かつ分岐または環を形成していてもよい炭素数1から7のアルキル基;またはヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基;であるか、あるいは
R2およびR3は一緒になって、-(CH2)q-[式中、qは2から5の整数である]を表し;
R4およびR5は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であるか、あるいは、R4およびR5は一緒になって、=C(R11)R12[式中、R11およびR12は、それぞれ独立して、水素原子、水酸基、核酸合成の保護基で保護された水酸基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、アミノ基、炭素数1から6の直鎖または分岐鎖アルコキシ基、炭素数1から6の直鎖または分岐鎖アルキルチオ基、炭素数1から6のシアノアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルアミノ基を表す]であり;
R6およびR7は、それぞれ独立して、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基であり;
R8は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基を表し
R9は、水素原子、水酸基、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、アミノ基、あるいは核酸合成の保護基で保護されたアミノ基であり;
R10は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
R13およびR14は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であり;
mは、0から2の整数であり;
nは、0から1の整数であり;
R10が水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
R10が-(C=(NHR17)+)-NR18R19[式中、R17、R18およびR19は、それぞれ独立して、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
Xは、酸素原子、硫黄原子、またはアミノ基であり;そして
Yは酸素原子または硫黄原子である。
Baseは、α群から選択される任意の置換基を1以上有していてもよいプリン-9-イル基、またはα群から選択される任意の置換基を1以上有していてもよい2-オキソ-1,2-ジヒドロピリミジン-1-イル基を表し、ここで、該α群は、水酸基、核酸合成の保護基で保護された水酸基、炭素数1から6の直鎖アルキル基、炭素数1から6の直鎖アルコキシ基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、炭素数1から6の直鎖アルキルチオ基、アミノ基、炭素数1から6の直鎖アルキルアミノ基、核酸合成の保護基で保護されたアミノ基、およびハロゲン原子からなり、
Aは、以下:
R1は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数2から7のアルケニル基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基、または核酸合成のアミノ基の保護基を表し;
R2およびR3は、それぞれ独立して、水素原子;ヘテロ原子を含んでいてもよい炭素数3から12のアリール基で置換されていてもよく、かつ分岐または環を形成していてもよい炭素数1から7のアルキル基;またはヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基;であるか、あるいは
R2およびR3は一緒になって、-(CH2)q-[式中、qは2から5の整数である]を表し;
R4およびR5は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であるか、あるいは、R4およびR5は一緒になって、=C(R11)R12[式中、R11およびR12は、それぞれ独立して、水素原子、水酸基、核酸合成の保護基で保護された水酸基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、アミノ基、炭素数1から6の直鎖または分岐鎖アルコキシ基、炭素数1から6の直鎖または分岐鎖アルキルチオ基、炭素数1から6のシアノアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルアミノ基を表す]であり;
R6およびR7は、それぞれ独立して、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基であり;
R8は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基を表し;
R9は、水素原子、水酸基、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、アミノ基、あるいは核酸合成の保護基で保護されたアミノ基であり;
R10は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
R13およびR14は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であり;
mは、0から2の整数であり;
nは、0から1の整数であり;
R10が-(C=(NHR17)+)-NR18R19[式中、R17、R18およびR19は、それぞれ独立して、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
Xは、酸素原子、硫黄原子、またはアミノ基であり;
Yは酸素原子または硫黄原子であり;そして
R22およびR23は、それぞれ独立して、水素原子、核酸合成の水酸基の保護基、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数2から7のアルケニル基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基、該α群から選択される任意の置換基を1以上有していてもよいアシル基、該α群から選択される任意の置換基を1以上有していてもよいシリル基、該α群から選択される任意の置換基を1以上有していてもよいリン酸基、核酸合成の保護基で保護されたリン酸基、-P(R24)R25[式中、R24およびR25は、それぞれ独立して、水酸基、核酸合成の保護基で保護された水酸基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、アミノ基、炭素数1から5のアルコキシ基、炭素数1から5のアルキルチオ基、炭素数1から6のシアノアルコキシ基、または炭素数1から6のアルキル基で置換されたジアルキルアミノ基を表す]を表す)
が挙げられる。
A(Y)^a^T(Y)^g^G(Y)^t^A(Y)^t^5(Y)^c^A(Y)^t^A(Y)^c^5(Y)^c^5(Y)^a(配列番号18)
AmNA[+5/+22]
A(Y)^c^5(Y)^a^A(Y)^a^T(Y)^g^G(Y)^t^A(Y)^t^5(Y)^c^A(Y)^t^A(Y)^c(配列番号19)
AmNA[+13/+30]
T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c^5(Y)^a^A(Y)^a^T(Y)^g^G(Y)^t(配列番号20)
AmNA[+15/+32]
A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c^5(Y)^a^A(Y)^a^T(Y)^g(配列番号21)
AmNA[+19/+36]
5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c^5(Y)^a(配列番号22)
AmNA[+23/+40]
5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号23)
AmNA[+27/+44]
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a(配列番号24)
AmNA[+31/+48]
A(Y)^t^5(Y)^t^A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g(配列番号25)
AmNA[+35/-2(3’)]
A(Y)^c^5(Y)^c^A(Y)^t^5(Y)^t^A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t(配列番号26)
上記の配列において、小文字=DNA、N(Y)=AmNA、5(Y)=AmNA_mC、^=ホスホロチオエート化(PS骨格)である。
A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号53)
AmNA[+21/+40]:
5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c(配列番号54)
AmNA[+23/+38]:
5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号55)
AmNA[+25/+40]:
5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a(配列番号56)
AmNA[+27/+46]:
5(Y)^t^A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a(配列番号57)
AmNA[+25/+44]:
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a(配列番号58)
AmNA[+27/+42]:
A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a(配列番号59)
AmNA[+29/+44]:
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a(配列番号60)
AmNA[+23/+44]:
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号61)
AmNA[+26/+43]:
G(Y)^a^T(Y)^c^A(Y)^c^A(Y)^c^T(Y)^c^T(Y)^a^G(Y)^t^A(Y)^a^A(Y)^t(配列番号62)
AmNA[+27/+44]_1/3:
A(Y)^g^a^T(Y)^c^a^5(Y)^a^c^T(Y)^c^t^A(Y)^g^t^A(Y)^a^a(配列番号63)
上記の配列において、小文字=DNA、N(Y)=AmNA、5(Y)=AmNA_mC、^=ホスホロチオエート化(PS骨格)である。
本発明の医薬組成物は、上記オリゴヌクレオチドまたはその薬理学上許容される塩を含有する。本発明の医薬組成物は、例えば、RESTのプロセシング(スプライシング)が関与する疾患の治療または予防に有用である。本発明の医薬組成物の対象疾患としては、例えば、癌疾患、心不全などが挙げられる。RESTのプロセシングに関連した癌疾患として、例えば、SRRM4が関与する癌(例えば、小細胞肺癌、前立腺癌(例えば、去勢抵抗性前立腺癌(CRPC))、乳癌)が挙げられる。このような癌疾患は、神経内分泌細胞に由来し得る。さらに本発明は、上記オリゴヌクレオチドまたはその薬理学上許容される塩を含有する癌治療薬を包含する。また、本発明は、上記オリゴヌクレオチドまたはその薬理学上許容される塩を含有する心不全治療薬を包含する。
本発明に関連するオリゴヌクレオチドを、Tetrahedron Letters 22,1859-1862(1981)、国際公開第2011/052436号等に記載される方法によって合成した。実施例1での設計に基づき、以下の式に示されるアミドBNA(AmNA)を含むオリゴヌクレオチドに関しては、国際公開第2011/052436号に記載の方法を参照して合成した:
アンチセンスオリゴヌクレオチドを、ヒトREST遺伝子(NCBI Reference Sequence: NG_029447.1 Homo sapiens RE1 silencing transcription factor (REST), RefSeqGene on chromosome 4.)のpre-mRNA(mRNA前駆体)を標的とするよう設計した。
A(Y)^a^A(Y)^c^G(Y)^g^A(Y)^a^A(Y)^t^T(Y)^g^A(Y)^c^A(Y)^t^T(Y)^t(配列番号12)
AmNA[-32/-15]:
T(Y)^g^5(Y)^a^T(Y)^a^G(Y)^t^A(Y)^g^A(Y)^a^A(Y)^a^A(Y)^c^G(Y)^g(配列番号13)
AmNA[-24/-7]:
5(Y)^a^A(Y)^t^G(Y)^g^A(Y)^a^T(Y)^g^5(Y)^a^T(Y)^a^G(Y)^t^A(Y)^g(配列番号14)
AmNA[-20/-3]:
G(Y)^g^T(Y)^c^5(Y)^a^A(Y)^t^G(Y)^g^A(Y)^a^T(Y)^g^5(Y)^a^T(Y)^a(配列番号15)
AmNA[-18/-1]:
5(Y)^t^G(Y)^g^T(Y)^c^5(Y)^a^A(Y)^t^G(Y)^g^A(Y)^a^T(Y)^g^5(Y)^a(配列番号16)
AmNA[-8/+10]:
5(Y)^c^A(Y)^t^A(Y)^c^5(Y)^c^5(Y)^a^5(Y)^t^G(Y)^g^T(Y)^c^5(Y)^a(配列番号17)
AmNA[+1/+18]:
A(Y)^a^T(Y)^g^G(Y)^t^A(Y)^t^5(Y)^c^A(Y)^t^A(Y)^c^5(Y)^c^5(Y)^a(配列番号18)
AmNA[+5/+22]:
A(Y)^c^5(Y)^a^A(Y)^a^T(Y)^g^G(Y)^t^A(Y)^t^5(Y)^c^A(Y)^t^A(Y)^c(配列番号19)
AmNA[+13/+30]:
T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c^5(Y)^a^A(Y)^a^T(Y)^g^G(Y)^t(配列番号20)
AmNA[+15/+32]:
A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c^5(Y)^a^A(Y)^a^T(Y)^g(配列番号21)
AmNA[+19/+36]:
5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c^5(Y)^a(配列番号22)
AmNA[+23/+40]:
5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号23)
AmNA[+27/+44]:
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a(配列番号24)
AmNA[+31/+48]:
A(Y)^t^5(Y)^t^A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g(配列番号25)
AmNA[+35/-2(3’)]:
A(Y)^c^5(Y)^c^A(Y)^t^5(Y)^t^A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t(配列番号26)
AmNA[+43/-10(3’)]:
G(Y)^a^A(Y)^t^A(Y)^c^A(Y)^t^A(Y)^c^5(Y)^c^A(Y)^t^5(Y)^t^A(Y)^g(配列番号27)
AmNA[-5(3’)/-22(3’)]:
T(Y)^a^5(Y)^a^T(Y)^t^5(Y)^t^A(Y)^c^5(Y)^t^G(Y)^a^A(Y)^t^A(Y)^c(配列番号28)
AmNA[-17(3’)/-34(3’)]:
G(Y)^c^A(Y)^t^A(Y)^a^G(Y)^a^G(Y)^t^A(Y)^a^T(Y)^a^5(Y)^a^T(Y)^t(配列番号29)
A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号53)
AmNA[+21/+40]:
5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t^A(Y)^c(配列番号54)
AmNA[+23/+38]:
5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号55)
AmNA[+25/+40]:
5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a(配列番号56)
AmNA[+27/+46]:
5(Y)^t^A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a(配列番号57)
AmNA[+25/+44]:
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a(配列番号58)
AmNA[+27/+42]:
A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a(配列番号59)
AmNA[+29/+44]:
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a(配列番号60)
AmNA[+23/+44]:
A(Y)^g^A(Y)^t^5(Y)^a^5(Y)^a^5(Y)^t^5(Y)^t^A(Y)^g^T(Y)^a^A(Y)^a^T(Y)^a^T(Y)^t(配列番号61)
AmNA[+26/+43]:
G(Y)^a^T(Y)^c^A(Y)^c^A(Y)^c^T(Y)^c^T(Y)^a^G(Y)^t^A(Y)^a^A(Y)^t(配列番号62)
AmNA[+27/+44]_1/3:
A(Y)^g^a^T(Y)^c^a^5(Y)^a^c^T(Y)^c^t^A(Y)^g^t^A(Y)^a^a(配列番号63)
実施例2で設計したうち10種のアンチセンスオリゴヌクレオチドについて、ヒトSCLC細胞(STC1)におけるインビトロでのRESTおよびsRESTの発現をRT-PCR法により調べ、sREST/REST発現比率を求めた。sREST/REST発現比率が低いほどNエキソンスキップが生じていると判断し、これらのアンチセンスオリゴヌクレオチドのスプライシング制御(Nエキソンスキッピング)効果を評価した。
SCLC細胞で異常発現しているSRRM4は内分泌性前立腺がん(NEPC)にも発現している。そこで適応をより拡大するために、SRRM4の発現が確認されている前立腺がん細胞株(VCaP)について評価した。
H146細胞(1.0×106細胞)にSSO(AmNA_[+31/+48])(0.1、1.0、2.0nmol)およびコントロールのAmNA_26をエレクトロポレーションにより導入し、96時間後に細胞を回収した。RNAを抽出し、β-actinとRESTとの各プライマーでRT-PCR後ポリアクリルアミドゲル電気泳動によりRESTとsRESTの解析を行った。
12種のアンチセンスオリゴヌクレオチドについて、種々の濃度で前立腺癌細胞(VCaP)に添加し、インビトロでのRESTおよびsRESTの発現をRT-PCR法により調べ、sREST/REST発現比率を求め、スプライシング制御(Nエキソンスキッピング)効果を評価した。
実施例6と同様の実験を、細胞の播種数およびSSOの導入方法を変えて行った。12種のアンチセンスオリゴヌクレオチドについて、種々の濃度で前立腺癌細胞(VCaP)に添加し、インビトロでのRESTおよびsRESTの発現をRT-PCR法により調べ、「%exclusion」を求め、スプライシング制御(Nエキソンスキッピング)効果を評価した。「%exclusion」は、オリゴヌクレオチドの「RESTのバンドの濃さとsRESTのバンドの濃さの和」に対するRESTのバンドの濃さの比率である。
実施例7で相対的なエキソンスキッピング活性が高いことが示されたAmNA[+23/+40]およびAmNA[+27/+44]について、さらに濃度を細かく振ってスプライシング制御効果を検証した。上記SSOについて、種々の濃度で前立腺癌細胞(VCaP)に添加し、インビトロでのRESTおよびsRESTの発現をRT-PCR法により調べ、「%exclusion」を求め、スプライシング制御(Nエキソンスキッピング)効果を評価した。
実施例7で相対的なエキソンスキッピング活性が高いことが示されたAmNA[+23/+40](AmNA_2340)およびAmNA[+27/+44](AmNA_2744)について、EC50(50%効果濃度)を解析した。上記SSOについて、種々の濃度で前立腺癌細胞(VCaP)に添加し、インビトロでのRESTおよびsRESTの発現をRT-PCR法により調べ、「%exclusion」を求め、スプライシング制御(Nエキソンスキッピング)効果を評価した。
実施例7で相対的なエキソンスキッピング活性が高いことが示されたAmNA[+23/+40](AmNA_2340)およびAmNA[+27/+44](AmNA_2744)を元に、配列長を変更、AmNAと天然核酸の位置を入れ替え、および/またはAmNAの導入数を変更することで、SSOの最適化を検討した。検討したSSOの配列長等の概要を図8に示す。また、ネガティブコントロールのSSOの検討も行った。AmNA[+35/-2]のATGC比及び人工核酸導入率(各塩基ごと)を変化させずにスクランブル配列を4配列設計(表1)し、VCaP細胞(1.0×105細胞)に対して被験オリゴヌクレオチド(10nM)をリポフェクション法で導入後、48時間後に細胞を回収し、定法に基づいて解析を行った。コントロール(モック)として、滅菌水を使用した。結果を図9に示す。その中で最もNTやmockと同等の活性を示す(すなわち%exclusionが1に近い)NC3を選出した。
AmNA[+23/+40](AmNA_2340)およびAmNA[+27/+44](AmNA_2744)、ならびに実施例10でスプライシング制御効果が示されたAmNA[+21/+40](AmNA_2140)およびAmNA[+23/+44](AmNA_2344)について、異なる細胞種でも同様にスプライシング制御効果を有するか否かを検証した。本実施例で用いた細胞は22Rv1であり、該細胞は、マウスで連続的に増殖した異種移植片に由来するヒト前立腺癌上皮細胞株である。上記SSOについて、1.0nMの濃度で前立腺癌細胞(22Rv1)に添加し、インビトロでのRESTおよびsRESTの発現をRT-PCR法により調べ、「%exclusion」を求め、スプライシング制御(Nエキソンスキッピング)効果を評価した。
AmNA_2340、AmNA_2744、AmNA_2140およびAmNA_2344を細胞に投与することで、SRRM4の遺伝子発現に対して影響を与えるか否かを検証した。SRRM4遺伝子は、RESTが発現を制御するRE1配列を有し、RESTの高発現はSRRM4遺伝子発現を抑制する。さらに、SRRM4タンパク質は、REST pre-mRNAのスプライシングを制御するタンパク質であり、SCLCでは、SRRM4タンパク質によりsRESTが高発現することが知られている(図15)。
実施例12で高いスプライシング効果およびSRRM4 mRNAの発現抑制効果を有するAmNA_2140について、in vivoで抗腫瘍効果を発揮するか検証した。コントロールとして、生理食塩水を使用した。腫瘍細胞をマウスに移植後(0日目)、3日目、6日目、9日目及び12日目に、体重(g)、腫瘍の長径(mm)、短径(mm)、腫瘍サイズ(体積)(mm3)を測定した。腫瘍サイズは、長径×短径2を2で除することで算出した。結果を図16および表2に示す。それぞれ、n=1である。
細胞株は、American Type Culture Collection (ATCC)より購入した。SCLC細胞(H146、H209)は浮遊細胞、前立腺がん細胞(VCaP、22Rv1)は接着細胞として培養した。培地はRPMI-1640(4,500mg/lグルコース、L-グルタミン、フェノールレッド、HEPES、ピルビン酸ナトリウム含有:Ref 187-02705:LOT ESH7003)にFBS(GibcoTMウシ胎児血清, qualified, Brazil:Ref 10270106:LOT 42F0288K)を10%となるように添加した。インキュベーター内は37℃、5%CO2とした。使用した細胞株は以下の通りである。SCLC細胞株:H146(HTB-173)、H209(HTB-172)、前立腺がん細胞株:VCaP(CRL-2876)、22Rv1(CRL-2505)
ASOのSCLC細胞へのトランスフェクション:
SCLC細胞(0.5×106細胞)をNeon(登録商標)Transfection System(Thermo Fisher Scientific社製)を使用し、添付文書に従ってトランスフェクションした。エレクトロポレーションのパラメーターについては最適化の結果、パルス電圧:1200V、パルス幅:20ms、パルス数:2 pulsesを選択した。
qRT-PCRによるSRRM4の発現解析では、トランスフェクションの24時間前に6-well plateに0.5×106細胞を1750μlのRPMI-1640で播種した。LipofectamineTM 3000(Thermo Fisher Scientific社製)が7.5μl/well、その他の項目は添付文書に従って調製したSRRM4-ASOとLipofectamineTM 3000 Reagentとの複合液250μlを各wellに添加した。24-well plateについては、トランスフェクション24時間前に0.1×106細胞を450μlのRPMI-1640で播種した。LipofectamineTM 3000(Thermo Fisher Scientific社製)が1.5μL/well、その他の項目は添付文書に従って得た複合液50μlを各wellに添加した。細胞生存率の評価では、トランスフェクションの24時間前に96-well plateに5.0×104細胞を100μlのRPMI-1640で播種した。LipofectamineTM 3000(Thermo Fisher Scientific社製)が0.3μl/well、その他の項目は製造元の指示に従って調製したSRRM4-ASOとLipofectamineTM 3000の複合液10μlを各wellに添加した。
Total RNAの抽出については、RNeasy Plus Micro Kit(Qiagen)を用い、手順は添付文書に従い実施した。Total RNAを260nmで分光光度的に定量し、100ng/16μlとなるようにRNase-free waterで調整した後、SuperScript VILO(Thermo Fischer Scientific社製)を4μl加えて逆転写反応(42℃、60分間)を実施した。
定量PCRについては、StepOnePlusTM Real-Time PCR Systems(Thermo Fisher Scientific)を用いて実施した。マスターミックスについてはTaqManTM Fast Advanced Master Mix (Thermo Fisher Scientific社製)を使用して調製した。SRRM4については、各プライマーを20μlの反応液中に10pmolで調製した。β-actinについては、TaqManTM β-Actin Detection Reagents (Thermo Fisher Scientific社製)の添付文書に従って調製した。逆転写反応より得たcDNAの1/100をqRT-PCRで解析した。反応条件については、95℃で20秒、95℃で3秒、60℃で30秒を40サイクルで実施した。相対的なmRNAレベルをβ-actineで補正し、ΔCt値により-ΔΔCt法にて解析した。すべての実験は3回以上実施し、平均値±SDを算出した。統計的有意性をt検定によって算出した。PCR産物について、アガロースゲル電気泳動およびシーケンス解析を行った:
hSRRM4 For.Primer:5'-tgacaaagacttgacaccacc-3'(配列番号30);
hSRRM4 Rev.Primer:5'-acctgcgtcgcttgtgttt-3'(配列番号31);
TaqMan Probe:5'-FAM-aggtcctcatcctatagcccatcgcct-TAMRA-3'(配列番号32)
RT反応で得たcDNAの1/10を、Hot Start Taq DNAポリメラーゼ(New England Biolabs社製)を用いて増幅した。反応条件については、95℃で30秒、95℃で15秒、58℃で15秒、68℃で30秒をβ-actinでは20サイクル、RESTおよびsRESTでは35サイクル行った後、68℃で2分間実施した。各プライマーを25μLの反応液中に各5pmolとなるように調製した。PCR産物については、5%Mini-PROTEAN TBE Precast Gels(BIO RAD)を使用して電気泳動を行った。泳動バッファーについては10×Tris-Borate-EDTA Buffer(ナカライテスク株式会社製)を0.5倍に希釈して使用した。
REST For.Primer:5'-gaacgcccatataaatgtgaa-3'(配列番号33);
REST Rev.Primer:5'-tttgaagttgcttctatctgctgt-3'(配列番号34);
β-actin For.Primer:5'-ggccgtcttcccctccatcg-3'(配列番号35);
β-actin Rev.Primer:5'-ccagttggtgacgatgccgtgc-3'(配列番号36)
細胞の生存率の評価を、WST8(Cell Counting Kit-8、Dojindo)を使用し添付文書に従って実施した。細胞を72時間培養した後、試薬を添加しInfinite M1000(Tecan)を使用して、450nmの吸光度を分析した。アッセイを3回以上実施し、再現性を確認した。
SRRM4 mRNAを標的とするアンチセンスDNAについては、株式会社ジーンデザインによって合成および精製されたものを使用した。
配列を以下の表3に示す:
実施例9で得られたデータをグラフ作成ソフトGraphPad Prismに導入し、4 Parameter Logistic(4PL)によって曲線回帰を行い、EC50を算出した。
7週齢のBALB/c Slc-nu/nuヌードマウス(雄)にhSCLC細胞(N417, 1×106細胞)をマウス背部に皮下移植し、腫瘍を形成させた。移植11日後に、マウスにSSO(AmNA_2140)を腹腔内投与した。腹腔内投与(10 mg/kg)は3日ごと、計4回行った。コントロールとして、生理食塩水を投与した。SSOの投与から12日後までマウスの腫瘍サイズについて観察を行った。得られた腫瘍サイズの経時変化をグラフ化し、生理食塩水を投与したコントロール群の腫瘍サイズの増大に対して、SSO投与群では腫瘍サイズの増大を抑える効果を確認した。
Claims (10)
- 配列番号1の塩基配列からなる標的領域中の少なくとも12塩基の連続する配列と相補的なヌクレオチド配列を含み、かつヒトREST pre-mRNAのプロセッシングにおけるNエキソンのスキッピングを誘導する、オリゴヌクレオチドまたはその薬理学上許容される塩。
- 前記オリゴヌクレオチドの長さが12~35塩基である、請求項1に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- 前記オリゴヌクレオチドまたはその薬理学上許容される塩が、以下の式(I)で表される、ヌクレオシド構造:
Baseは、α群から選択される任意の置換基を1以上有していてもよいプリン-9-イル基、またはα群から選択される任意の置換基を1以上有していてもよい2-オキソ-1,2-ジヒドロピリミジン-1-イル基を表し、ここで、該α群は、水酸基、核酸合成の保護基で保護された水酸基、炭素数1から6の直鎖アルキル基、炭素数1から6の直鎖アルコキシ基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、炭素数1から6の直鎖アルキルチオ基、アミノ基、炭素数1から6の直鎖アルキルアミノ基、核酸合成の保護基で保護されたアミノ基、およびハロゲン原子からなり、
Aは、以下:
R1は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数2から7のアルケニル基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール基、該α群から選択される任意の置換基を1以上有していてもよくそしてヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基、または核酸合成のアミノ基の保護基を表し;
R2およびR3は、それぞれ独立して、水素原子;ヘテロ原子を含んでいてもよい炭素数3から12のアリール基で置換されていてもよく、かつ分岐または環を形成していてもよい炭素数1から7のアルキル基;またはヘテロ原子を含んでいてもよい炭素数3から12のアリール部分を有するアラルキル基;であるか、あるいは
R2およびR3は一緒になって、-(CH2)q-[式中、qは2から5の整数である]を表し;
R4およびR5は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であるか、あるいは、R4およびR5は一緒になって、=C(R11)R12[式中、R11およびR12は、それぞれ独立して、水素原子、水酸基、核酸合成の保護基で保護された水酸基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、アミノ基、炭素数1から6の直鎖または分岐鎖アルコキシ基、炭素数1から6の直鎖または分岐鎖アルキルチオ基、炭素数1から6のシアノアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルアミノ基を表す]であり;
R6およびR7は、それぞれ独立して、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基であり;
R8は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、または炭素数1から6の直鎖または分岐鎖アルキルチオ基を表し;
R9は、水素原子、水酸基、分岐または環を形成していてもよい炭素数1から7のアルキル基、分岐または環を形成していてもよい炭素数1から7のアルコキシ基、アミノ基、あるいは核酸合成の保護基で保護されたアミノ基であり;
R10は、水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
R13およびR14は、それぞれ独立して、水素原子;水酸基;分岐または環を形成していてもよい炭素数1から7のアルキル基;分岐または環を形成していてもよい炭素数1から7のアルコキシ基;アミノ基;および核酸合成の保護基で保護されたアミノ基;からなる群から選択される基であり;
mは、0から2の整数であり;
nは、0から1の整数であり;
R10が水素原子、分岐または環を形成していてもよい炭素数1から7のアルキル基、アミノ基の保護基、または
R10が-(C=(NHR17)+)-NR18R19である場合、pは0であり;
Xは、酸素原子、硫黄原子、またはアミノ基であり;そして
Yは酸素原子または硫黄原子である)
の少なくとも1つを含む、
請求項1または2に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。 - 前記オリゴヌクレオチドを構成するヌクレオチド間の結合が、ホスホロチオエートを含む、請求項1から3のいずれかに記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- 前記オリゴヌクレオチドの塩基配列が、配列番号3~11および配列番号40~49のいずれかの塩基配列を含む、請求項1から4に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- 請求項1から6のいずれかに記載のオリゴヌクレオチドまたはその薬理学上許容される塩を含む、医薬組成物。
- 癌治療薬である、請求項7に記載の医薬組成物。
- 小細胞肺癌、前立腺癌および乳癌よりなる群から選択される少なくとも1つの癌の治療に用いられる、請求項8に記載の医薬組成物。
- 心不全治療薬である、請求項7に記載の医薬組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/547,071 US20240148775A1 (en) | 2021-02-25 | 2022-02-25 | Oligonucleotide for inducing n-exon skipping during rest mrna precursor processing |
JP2023502564A JPWO2022181807A1 (ja) | 2021-02-25 | 2022-02-25 | |
EP22759841.4A EP4299744A1 (en) | 2021-02-25 | 2022-02-25 | Oligonucleotide for inducing n-exon skipping during rest mrna precursor processing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021029327 | 2021-02-25 | ||
JP2021-029327 | 2021-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022181807A1 true WO2022181807A1 (ja) | 2022-09-01 |
Family
ID=83049257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/008079 WO2022181807A1 (ja) | 2021-02-25 | 2022-02-25 | REST mRNA前駆体のプロセシングにおけるNエキソンのスキッピングを誘導するオリゴヌクレオチド |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240148775A1 (ja) |
EP (1) | EP4299744A1 (ja) |
JP (1) | JPWO2022181807A1 (ja) |
WO (1) | WO2022181807A1 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011052436A1 (ja) | 2009-10-29 | 2011-05-05 | 国立大学法人大阪大学 | 架橋型人工ヌクレオシドおよびヌクレオチド |
JP2011520444A (ja) * | 2008-05-14 | 2011-07-21 | プロセンサ テクノロジーズ ベー.フェー. | デュシェンヌ型筋ジストロフィーにおける効率的なエクソン(44)スキッピングのための方法及び関連手段 |
WO2014046212A1 (ja) | 2012-09-21 | 2014-03-27 | 国立大学法人大阪大学 | グアニジン架橋を有する人工ヌクレオシドおよびオリゴヌクレオチド |
WO2015012175A1 (ja) * | 2013-07-22 | 2015-01-29 | 学校法人関西医科大学 | 小細胞肺がんの診断薬及び治療薬 |
WO2015125783A1 (ja) | 2014-02-18 | 2015-08-27 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
WO2016089928A1 (en) * | 2014-12-01 | 2016-06-09 | Weitz Andrew C | Methods for treating and assessing tumor invasion and metastasis |
WO2018139679A1 (ja) * | 2017-01-30 | 2018-08-02 | 賢二 中野 | 癌浸潤または転移阻害核酸薬および癌バイオマーカー |
WO2020027227A1 (ja) | 2018-07-31 | 2020-02-06 | 国立大学法人大阪大学 | オリゴヌクレオチドを含有する小細胞肺癌治療薬 |
JP2021029327A (ja) | 2019-08-19 | 2021-03-01 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
-
2022
- 2022-02-25 WO PCT/JP2022/008079 patent/WO2022181807A1/ja active Application Filing
- 2022-02-25 US US18/547,071 patent/US20240148775A1/en active Pending
- 2022-02-25 JP JP2023502564A patent/JPWO2022181807A1/ja active Pending
- 2022-02-25 EP EP22759841.4A patent/EP4299744A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011520444A (ja) * | 2008-05-14 | 2011-07-21 | プロセンサ テクノロジーズ ベー.フェー. | デュシェンヌ型筋ジストロフィーにおける効率的なエクソン(44)スキッピングのための方法及び関連手段 |
WO2011052436A1 (ja) | 2009-10-29 | 2011-05-05 | 国立大学法人大阪大学 | 架橋型人工ヌクレオシドおよびヌクレオチド |
JP2014043462A (ja) | 2009-10-29 | 2014-03-13 | Osaka Univ | 架橋型人工ヌクレオシドおよびヌクレオチド |
WO2014046212A1 (ja) | 2012-09-21 | 2014-03-27 | 国立大学法人大阪大学 | グアニジン架橋を有する人工ヌクレオシドおよびオリゴヌクレオチド |
WO2015012175A1 (ja) * | 2013-07-22 | 2015-01-29 | 学校法人関西医科大学 | 小細胞肺がんの診断薬及び治療薬 |
WO2015125783A1 (ja) | 2014-02-18 | 2015-08-27 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
WO2016089928A1 (en) * | 2014-12-01 | 2016-06-09 | Weitz Andrew C | Methods for treating and assessing tumor invasion and metastasis |
WO2018139679A1 (ja) * | 2017-01-30 | 2018-08-02 | 賢二 中野 | 癌浸潤または転移阻害核酸薬および癌バイオマーカー |
WO2020027227A1 (ja) | 2018-07-31 | 2020-02-06 | 国立大学法人大阪大学 | オリゴヌクレオチドを含有する小細胞肺癌治療薬 |
JP2021029327A (ja) | 2019-08-19 | 2021-03-01 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
Non-Patent Citations (7)
Title |
---|
"NCBI", Database accession no. NG_029447.1 |
CHEN GUO-LIN, MILLER GREGORY M.: "Extensive Alternative Splicing of the Repressor Element Silencing Transcription Factor Linked to Cancer", PLOS ONE, vol. 8, no. 4, 16 April 2013 (2013-04-16), pages e62217, XP055961845, DOI: 10.1371/journal.pone.0062217 * |
CONFERENCE ABSTRACTS AND POSTER OF 16TH ANNUAL MEETING OF THE OLIGONUCLEOTIDE THERAPEUTICS SOCIETY, 27 September 2020 (2020-09-27) |
M. KUWAHARA ET AL., NUCLEIC ACIDS RES., vol. 36, no. 13, 2008, pages 4257 - 65 |
ORTUÑO-PINEDA CARLOS, JOSÉ MANUEL GALINDO-ROSALES, JOSÉ VICTOR CALDERÓN-SALINAS, NICOLÁS VILLEGAS-SEPÚLVEDA, ODILA SAUCEDO-CÁRDENA: "Binding of hnRNP H and U2AF65 to Respective G-codes and a Poly-Uridine Tract Collaborate in the N50-5'ss Selection of the REST N Exon in H69 Cells", PLOS ONE, vol. 7, no. 7, 5 July 2012 (2012-07-05), pages e40315, XP055961842, DOI: 10.1371/journal.pone.0040315 * |
TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859 - 1862 |
ZHANG DONGHONG, WU BINGRUO, WANG PING, WANG YIDONG, LU PENGFEI, NECHIPORUK TAMILLA, FLOSS THOMAS, GREALLY JOHN M., ZHENG DEYOU, ZH: "Non-CpG methylation by DNMT3B facilitates REST binding and gene silencing in developing mouse hearts", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 45, no. 6, 7 April 2017 (2017-04-07), GB , pages 3102 - 3115, XP055961837, ISSN: 0305-1048, DOI: 10.1093/nar/gkw1258 * |
Also Published As
Publication number | Publication date |
---|---|
EP4299744A1 (en) | 2024-01-03 |
US20240148775A1 (en) | 2024-05-09 |
JPWO2022181807A1 (ja) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6233903B2 (ja) | 架橋型ヌクレオシドおよびヌクレオチド | |
JP7473113B2 (ja) | オリゴヌクレオチドを含有する小細胞肺癌治療薬 | |
JP6562517B2 (ja) | 架橋型ヌクレオシドおよびヌクレオチド | |
EP3919501A1 (en) | 5'-modified nucleoside and nucleotide using same | |
US11234995B2 (en) | α-synuclein expression inhibitor | |
JP2021527437A (ja) | Scn9a発現を調節するためのオリゴヌクレオチド | |
CA2902260A1 (en) | Tricyclic nucleosides and oligomeric compounds prepared therefrom | |
JP2024041845A (ja) | ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド | |
WO2019009298A1 (ja) | α-シヌクレイン発現抑制剤 | |
JP2020055750A (ja) | 癌浸潤または転移阻害核酸薬 | |
EP3925965A1 (en) | 5'-modified nucleoside and nucleotide using same | |
CN110691849A (zh) | 用于调节htra1表达的反义寡核苷酸 | |
WO2022181807A1 (ja) | REST mRNA前駆体のプロセシングにおけるNエキソンのスキッピングを誘導するオリゴヌクレオチド | |
WO2023149038A1 (ja) | フェノキサジン誘導体およびそれを用いたドラッグデリバリーシステム製剤 | |
WO2023167094A1 (ja) | 5'位修飾ヌクレオシドおよびそれを用いたヌクレオチド | |
WO2022215704A1 (ja) | リガンド-核酸コンジュゲート体 | |
JP7288052B2 (ja) | Scn9a発現を阻害するための増強されたオリゴヌクレオチド | |
CN114369130B (zh) | 修饰的硫代寡核苷酸及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22759841 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023502564 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18547071 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022759841 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022759841 Country of ref document: EP Effective date: 20230925 |